Search by Journal
- HOME
- > Search by Journal
- > Journal of Japanese Society of Pharmaceutical Oncology
Journal of Japanese Society of Pharmaceutical Oncology
Volume 36, Issue / 2024
English Article 
Japanese Article- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
|
It is ... from butterfly effect ... small flap to the development of the clinical tumor pharmacy 牧野好倫 Journal of Japanese Society of Pharmaceutical Oncology 36: 1-1, 2024. |
|---|
|
|
Activity contents in Japanese clinical tumor Pharmaceutical Society toward 2024 and future problem 近藤直樹 Journal of Japanese Society of Pharmaceutical Oncology 36: 2-2, 2024. |
|---|
|
|
Butterfly effect in the cancer medical care 佐伯俊昭 Journal of Japanese Society of Pharmaceutical Oncology 36: 3-3, 2024. |
|---|
|
|
Science and a design of the vaccine: Link of an infection and cancer 石井健 Journal of Japanese Society of Pharmaceutical Oncology 36: 4-4, 2024. |
|---|
|
|
Pharmacokinetics for pharmacists 笹川大介 Journal of Japanese Society of Pharmaceutical Oncology 36: 5-5, 2024. |
|---|
|
|
Basic knowledge of the colon cancer medical therapy 秦晃二郎 Journal of Japanese Society of Pharmaceutical Oncology 36: 7-7, 2024. |
|---|
|
|
Basic knowledge of the lung cancer medical therapy 組橋由記 Journal of Japanese Society of Pharmaceutical Oncology 36: 8-8, 2024. |
|---|
|
|
Basics of the breast cancer medical therapy 宮本康敬 Journal of Japanese Society of Pharmaceutical Oncology 36: 9-9, 2024. |
|---|
|
|
Basic knowledge of the pancreatic cancer medical therapy 篠原佳祐 Journal of Japanese Society of Pharmaceutical Oncology 36: 10-10, 2024. |
|---|
|
|
It is pharmaceutical management of the blood cancer medical therapy skill up 土手賢史 Journal of Japanese Society of Pharmaceutical Oncology 36: 11-11, 2024. |
|---|
|
|
Symposium 1. What should I do at such time? ! Of the steroid after the side effect onset of ... immunity checkpoint inhibitor and the embarrassing example steroid which there was about management at ... fruit verge of the immunosuppressive drug let's have is professional, and initiate me into an art; than ... organizer ...! 藤堂真紀, 藤田あゆみ Journal of Japanese Society of Pharmaceutical Oncology 36: 12-12, 2024. |
|---|
|
|
S1-1. The need of the medicine medicine cooperation in steroid management and steroid refractoriness case - steroid management of irAE meeting by daily life 南晴奈 Journal of Japanese Society of Pharmaceutical Oncology 36: 13-13, 2024. |
|---|
|
|
S1-2. Problems in normal business routine and the medicine medicine cooperation for ICI treated patients 宮田香織 Journal of Japanese Society of Pharmaceutical Oncology 36: 14-14, 2024. |
|---|
|
|
S1-3. To use an immunosuppressive drug, a biological drug of the mechanism except the steroid on the management of steroid refractoriness irAE appropriately 峯村信嘉 Journal of Japanese Society of Pharmaceutical Oncology 36: 15-15, 2024. |
|---|
|
|
Symposium 2. Than advice - organizer of coping from Up-To-Date guidelines to chemotherapy-induced peripheral neuropathy to think about ... 大矢浩之, 中島寿久 Journal of Japanese Society of Pharmaceutical Oncology 36: 16-16, 2024. |
|---|
|
|
S2-1. For neuropathy guidelines Up Date - bionomics improvement with the cancer chemotherapy 華井明子 Journal of Japanese Society of Pharmaceutical Oncology 36: 17-17, 2024. |
|---|
|
|
S2-2. Evidence of the treatment with neuropathy guidelines Up Date - medical therapy with the cancer chemotherapy 中島寿久 Journal of Japanese Society of Pharmaceutical Oncology 36: 18-18, 2024. |
|---|
|
|
S2-3. Prophylactic evidence with the neuropathy guidelines Up Date - medical therapy with the cancer chemotherapy 渡邊大地 Journal of Japanese Society of Pharmaceutical Oncology 36: 19-19, 2024. |
|---|
|
|
S2-4. We think about CIPN in the true clinical practice 中村匡志 Journal of Japanese Society of Pharmaceutical Oncology 36: 20-20, 2024. |
|---|
|
|
Symposium 3. Where can a pharmacist step into the nourishment management to cancer-treated patients to? Than ... organizer ... 高山俊輔 Journal of Japanese Society of Pharmaceutical Oncology 36: 21-21, 2024. |
|---|
|
|
S3-1. We regard the nourishment management in cancer-treated patients as the purpose explanation of this symposium 高山俊輔 Journal of Japanese Society of Pharmaceutical Oncology 36: 22-22, 2024. |
|---|
|
|
S3-2. Cooperation between nourishment intervention and pharmacists of the dietitian in the health insurance pharmacy 下村直樹 Journal of Japanese Society of Pharmaceutical Oncology 36: 23-23, 2024. |
|---|
|
|
S3-3. Pharmacist + dietician = patients satisfaction improves 滝澤康志 Journal of Japanese Society of Pharmaceutical Oncology 36: 24-24, 2024. |
|---|
|
|
S3-4. Seek it for a key of the nourishment management of cancer-treated patients and the cooperation with the pharmacist 森ひろみ Journal of Japanese Society of Pharmaceutical Oncology 36: 25-25, 2024. |
|---|
|
|
S3-5. Medication support and exposure measures of the simple suspension method to cancer-treated patients 青木学一1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 26-26, 2024. |
|---|
|
|
Symposium 4. Is it good that continue leaving MOTTAINAI in ... healthcare setting thinking about cancer medical care from medical economy as it is; than ... organizer ... 鍛治園誠, 郷真貴子 Journal of Japanese Society of Pharmaceutical Oncology 36: 27-27, 2024. |
|---|
|
|
S4-1. Problems about the medical economy to meet on the site of cancer treatment 鍛治園誠 Journal of Japanese Society of Pharmaceutical Oncology 36: 28-28, 2024. |
|---|
|
|
S4-2. MOTTAINAI NOW 原田知彦 Journal of Japanese Society of Pharmaceutical Oncology 36: 29-29, 2024. |
|---|
|
|
S4-3. Change importance - MOTTAINAI of disseminating information from a pharmacist for the medical expenses reduction to the clinical studies; and ... 宇佐美英績 Journal of Japanese Society of Pharmaceutical Oncology 36: 30-30, 2024. |
|---|
|
|
S4-4. To sustain the unsustainable 國頭英夫 Journal of Japanese Society of Pharmaceutical Oncology 36: 31-31, 2024. |
|---|
|
|
Symposium 5. Than advice - organizer of medical DX in the cancer domain ... 小枝伸行, 和田敦 Journal of Japanese Society of Pharmaceutical Oncology 36: 32-32, 2024. |
|---|
|
|
S5-1. About efforts of medical DX in Ministry of Health, Labour and Welfare 新畑覚也 Journal of Japanese Society of Pharmaceutical Oncology 36: 33-33, 2024. |
|---|
|
|
S5-2. With medical DX in cancer treatment judging from a viewpoint of a physician, the drugstore management 狭間研至 Journal of Japanese Society of Pharmaceutical Oncology 36: 34-34, 2024. |
|---|
|
|
S5-3. VBCH (Value-Based Health Care) and possibility of the electronic edition prescription notebook in the cancer domain 広井嘉栄 Journal of Japanese Society of Pharmaceutical Oncology 36: 35-35, 2024. |
|---|
|
|
Symposium 6. What should I do? Than sustainable successor upbringing and career path - organizer of ... qualified person ... 高田慎也, 森本真宗 Journal of Japanese Society of Pharmaceutical Oncology 36: 36-36, 2024. |
|---|
|
|
S6-1. Backstage ... of ... pharmacist upbringing to learn through the multi-type of job collaboration and an outcome evaluation together 池末裕明 Journal of Japanese Society of Pharmaceutical Oncology 36: 37-37, 2024. |
|---|
|
|
S6-2. To become pharmacist upbringing ... sought pharmacist working by tissue with the wide area transfer; ... 衛藤智章 Journal of Japanese Society of Pharmaceutical Oncology 36: 38-38, 2024. |
|---|
|
|
S6-3. Trial and error to tie a specialized pharmacist in Hiroshima Municipal Hospital system 阪田安彦, 北本真一, 宮森伸一 Journal of Japanese Society of Pharmaceutical Oncology 36: 39-39, 2024. |
|---|
|
|
S6-4. Finding a field where you are needed and can shine - Nakajima Pharmacy's efforts to acquire professional qualifications - 谷口亮央 Journal of Japanese Society of Pharmaceutical Oncology 36: 40-40, 2024. |
|---|
|
|
Symposium 7. What would you do at such time? Than ... organizer thinking about treatment with anticancer medicine for ... special population ... 大神正宏, 丹田雅明 Journal of Japanese Society of Pharmaceutical Oncology 36: 41-41, 2024. |
|---|
|
|
S7-1. The preparation to onset of drug interaction 鈴木嘉治 Journal of Japanese Society of Pharmaceutical Oncology 36: 42-42, 2024. |
|---|
|
|
S7-2. Dose design for the patients with the liver damage 前田章光 Journal of Japanese Society of Pharmaceutical Oncology 36: 43-43, 2024. |
|---|
|
|
S7-3. Cancer medical therapy to patients with the chronic kidney disease 渋谷悠真 Journal of Japanese Society of Pharmaceutical Oncology 36: 44-44, 2024. |
|---|
|
|
S7-4. Dose design in consideration of the need, physique of the cooperation with the dentist 早坂大 Journal of Japanese Society of Pharmaceutical Oncology 36: 45-45, 2024. |
|---|
|
|
Symposium 8. What pharmacists can do for life after cancer treatment: How can we address late complications? - From the organizer - 日置三紀, 小室雅人 Journal of Japanese Society of Pharmaceutical Oncology 36: 46-46, 2024. |
|---|
|
|
S8-1. We are expected by cancer measures and a pharmacist of our country 文靖子 Journal of Japanese Society of Pharmaceutical Oncology 36: 47-47, 2024. |
|---|
|
|
S8-2. Role of the pharmacist in a cancer, the reproductive medicine 佐々木実緒 Journal of Japanese Society of Pharmaceutical Oncology 36: 48-48, 2024. |
|---|
|
|
S8-3. Relation of the pharmacist for the late complications of the cancer survivor 小室雅人 Journal of Japanese Society of Pharmaceutical Oncology 36: 49-49, 2024. |
|---|
|
|
S8-4. Present to me from me which became sterile of the thing that cancer was cured 大谷貴子 Journal of Japanese Society of Pharmaceutical Oncology 36: 50-50, 2024. |
|---|
|
|
Symposium 9. Than clinical reasoning - organizer of the pharmacist playing an active part in various healthcare settings ... 葉山達也 Journal of Japanese Society of Pharmaceutical Oncology 36: 51-51, 2024. |
|---|
|
|
S9-1. We put the viewpoints that are general and professional together and challenge side effect suspicion 今井徹 Journal of Japanese Society of Pharmaceutical Oncology 36: 52-52, 2024. |
|---|
|
|
S9-2. The medicine medicine from a side effect early detection telephone follow-up of the cancer medical therapy cooperates in ethical pharmacy 濱里大吉 Journal of Japanese Society of Pharmaceutical Oncology 36: 53-53, 2024. |
|---|
|
|
S9-3. 2 case ... of cause search - cutaneous symptom and retching of the symptom that developed during cancer medical therapy 吉田幸司 Journal of Japanese Society of Pharmaceutical Oncology 36: 54-54, 2024. |
|---|
|
|
S9-4. The clinical reasoning in the health insurance pharmacy utilizing the medicine medicine cooperation 大熊祐美 Journal of Japanese Society of Pharmaceutical Oncology 36: 55-55, 2024. |
|---|
|
|
Symposium 10. Than - - organizer who learn from advice - business of the case report, and wears a clinical study skill ... 宮田広樹, 内山将伸 Journal of Japanese Society of Pharmaceutical Oncology 36: 56-56, 2024. |
|---|
|
|
S10-1. Difference between case report and case report to publish as a treatise for a specialty, the authorized pharmacist acquisition 百賢二 Journal of Japanese Society of Pharmaceutical Oncology 36: 57-57, 2024. |
|---|
|
|
S10-2. The CARE guidelines (CAse REports) 川口崇 Journal of Japanese Society of Pharmaceutical Oncology 36: 58-58, 2024. |
|---|
|
|
S10-3. The current situation and problem of the case report to think about in the settings glance of the drugstore pharmacist 三星勇輝 Journal of Japanese Society of Pharmaceutical Oncology 36: 59-59, 2024. |
|---|
|
|
Symposium 11. Than method - organizer who let's work properly if do it anyway, and expands the workshop of ... cooperation enhancement addition institution standard requirements ... 小井土啓一, 堀越建一 Journal of Japanese Society of Pharmaceutical Oncology 36: 60-60, 2024. |
|---|
|
|
S11-1. To exceed a hurdle of specific drug management instruction addition 2 吉留実慧子1), 槙原克也2) Journal of Japanese Society of Pharmaceutical Oncology 36: 61-61, 2024. |
|---|
|
|
S11-2. It is ... for patients support in the whole efforts - area of the periodical workshop holding that collaborated with local pharmacist society 飯田遼 Journal of Japanese Society of Pharmaceutical Oncology 36: 62-62, 2024. |
|---|
|
|
S11-3. Nara doing it anyway and ... which digs up needs for the hospital pharmacist from the workshop as no hearing - institution requirements 徳留雄太 Journal of Japanese Society of Pharmaceutical Oncology 36: 63-63, 2024. |
|---|
|
|
S11-4. The end that held the online workshop for the local health insurance drugstore continuously for three years 小井土啓一 Journal of Japanese Society of Pharmaceutical Oncology 36: 64-64, 2024. |
|---|
|
|
Symposium 12. Not parts, let's support it by total, and study the side effect management of patients in Onco-Cardiology, and spark a pharmacist effect [Japanese tumor circulatory organ association cosponsorship symposium]; than - organizer ... 藤堂真紀, 高田慎也 Journal of Japanese Society of Pharmaceutical Oncology 36: 65-65, 2024. |
|---|
|
|
S12-1. Normal business routine and the result that adopted tumor angiocardiology 梅原健吾, 高田慎也, 山岸佳代, 橋下浩紀 Journal of Japanese Society of Pharmaceutical Oncology 36: 66-66, 2024. |
|---|
|
|
S12-2. What a health insurance pharmacy can contribute to in the tumor circulatory organ 斉藤和寛 Journal of Japanese Society of Pharmaceutical Oncology 36: 67-67, 2024. |
|---|
|
|
S12-3. A pharmacist supports evolving cancer treatment from a viewpoint of Onco-Cardiology! 田村雄一 Journal of Japanese Society of Pharmaceutical Oncology 36: 68-68, 2024. |
|---|
|
|
Symposium 13. Than how to build conversion and studies - organizer from real - CQ of the exploratory approach by the pharmacist to RQ ... 内山将伸, 葉山達也 Journal of Japanese Society of Pharmaceutical Oncology 36: 69-69, 2024. |
|---|
|
|
S13-1. It is ... mainly on structuring it from point - CQ which you should suppress to make an appropriate study plan to RQ 林稔展 Journal of Japanese Society of Pharmaceutical Oncology 36: 70-70, 2024. |
|---|
|
|
S13-2. Practice of the clinical studies that started from the medical data analysis 新村貴博1,2), 八木健太1,2), 相澤風花2,3), 石澤有紀2,4), 濱野裕章5), 合田光寛2,3), 座間味義人5), 石澤啓介1,2,3) Journal of Japanese Society of Pharmaceutical Oncology 36: 71-71, 2024. |
|---|
|
|
S13-3. Approach of searching it in childhood cancer treatment 岩田直大, 蔵田靖子, 田中雄太, 濱野裕章, 鍛治園誠, 座間味義人 Journal of Japanese Society of Pharmaceutical Oncology 36: 72-72, 2024. |
|---|
|
|
S13-4. With the difference with example joint ownership - academia, and the like in clinical studies to work on in municipal hospital? ... 小澤有輝 Journal of Japanese Society of Pharmaceutical Oncology 36: 73-73, 2024. |
|---|
|
|
Symposium 14. Than thing - organizer expecting it in efforts and the future of the JASPO foreign countries training dispatch business report - overseas deployment business in 2023 ... 太田貴洋, 鈴木真也 Journal of Japanese Society of Pharmaceutical Oncology 36: 74-74, 2024. |
|---|
|
|
S14-1. Obtained it through efforts and the training to improvement in quality of the overseas deployment business education; learn; is ... for a step named ... next 久松大祐 Journal of Japanese Society of Pharmaceutical Oncology 36: 75-75, 2024. |
|---|
|
|
S14-2. About the future of the drugstore pharmacist thinking from difference between Japan and United States 五十嵐爽 Journal of Japanese Society of Pharmaceutical Oncology 36: 76-76, 2024. |
|---|
|
|
S14-3. Clinical duties, education system ... of "rial" - pharmacist of the American medical care and pharmacist who learned through the overseas deployment training 坂本靖宜 Journal of Japanese Society of Pharmaceutical Oncology 36: 77-77, 2024. |
|---|
|
|
S14-4. Efforts to the way and cancer treatment of the pharmacist education to learn from the "All Roads Lead to Rome" United States 堀之内藍 Journal of Japanese Society of Pharmaceutical Oncology 36: 78-78, 2024. |
|---|
|
S14-5. Pharmacy Residency Training in the United States Lisa Modelevsky Journal of Japanese Society of Pharmaceutical Oncology 36: 79-79, 2024. |
|---|
|
|
S14-6. Expect it of a person of coming overseas training 太田貴洋 Journal of Japanese Society of Pharmaceutical Oncology 36: 80-80, 2024. |
|---|
|
|
Symposium 15. How does everybody do it? Than ... organizer making promote in-hospital exposure measures by occupational exposure measures - butterfly effect in the anticancer medicine drastically ... 谷川大夢, 小林一男 Journal of Japanese Society of Pharmaceutical Oncology 36: 81-81, 2024. |
|---|
|
|
S15-1. Is the environmental exposure investigation of the anticancer medicine really necessary? - Management cycle - to be able to connect to the exposure measures 三宅知宏 Journal of Japanese Society of Pharmaceutical Oncology 36: 82-82, 2024. |
|---|
|
|
S15-2. With the environment that prepares anticancer medicine in peace, and can be given? Efforts ... of our hospital for ... environmental exposure reduction 福岡智宏 Journal of Japanese Society of Pharmaceutical Oncology 36: 83-83, 2024. |
|---|
|
|
S15-3. An anticancer medicine preparation: Exposure to anticancer medicine measures to take by measures, and the like 石丸博雅 Journal of Japanese Society of Pharmaceutical Oncology 36: 84-84, 2024. |
|---|
|
|
S15-4. For the anticancer medicine exposure measures as the institution specialized in cancer treatment 清水久範 Journal of Japanese Society of Pharmaceutical Oncology 36: 85-85, 2024. |
|---|
|
|
Symposium 16. Than heart and correspondence and solution - organizer of the psychosocial problem that physical - pharmacist describes fighting against a cancer ... 高見陽一郎, 志田敏宏 Journal of Japanese Society of Pharmaceutical Oncology 36: 86-86, 2024. |
|---|
|
|
S16-1. With the psychosocial problem of patients with cancer 榎戸正則 Journal of Japanese Society of Pharmaceutical Oncology 36: 87-87, 2024. |
|---|
|
|
S16-2. Patients interview ... which takes the depth of necessary thing - heart as hospital pharmacist to sympathize with patients with cancer 木本真司 Journal of Japanese Society of Pharmaceutical Oncology 36: 88-88, 2024. |
|---|
|
|
S16-3. It is ... from the position of ... visit pharmacist snuggling up to a change of the psychosocial anxiety of patients in the home medical treatment after a discharge 中島美紀 Journal of Japanese Society of Pharmaceutical Oncology 36: 89-89, 2024. |
|---|
|
|
S16-4. The reporting that is necessary for seamless discharge support 星利佳 Journal of Japanese Society of Pharmaceutical Oncology 36: 90-90, 2024. |
|---|
|
|
S16-5. Cancer salon as the prop of the treatment that a health insurance pharmacy works on 松元享平 Journal of Japanese Society of Pharmaceutical Oncology 36: 91-91, 2024. |
|---|
|
|
Symposium 17. Than the message to a young person researcher carrying from back face - this of the pharmacist-led clinical study to be able to talk about now, tips and tricks - organizer of the clinical studies planning delicious twice once ... 鈴木賢一, 牧野好倫 Journal of Japanese Society of Pharmaceutical Oncology 36: 92-92, 2024. |
|---|
|
|
S17-1. Refute trouble story - IRB until TDM study start of the debate (1) amrubicin therapy; ... 鈴木賢一 Journal of Japanese Society of Pharmaceutical Oncology 36: 93-93, 2024. |
|---|
|
|
S17-2. "The distance until debate (2) TRIPLE study design decision" 牧野好倫 Journal of Japanese Society of Pharmaceutical Oncology 36: 94-94, 2024. |
|---|
|
|
Symposium 18. What is the problem of the cooperation in the area? To remove the wall? Than ... organizer ... 大塚昌孝, 村田勇人 Journal of Japanese Society of Pharmaceutical Oncology 36: 95-95, 2024. |
|---|
|
|
S18-1. How to break walls from a questionnaire to the cooperation between the drugstores which we saw 大塚昌孝 Journal of Japanese Society of Pharmaceutical Oncology 36: 96-96, 2024. |
|---|
|
|
S18-2. The role of the drugstore pharmacist in the area and promotion of the community medical care cooperation 小川雄大 Journal of Japanese Society of Pharmaceutical Oncology 36: 97-97, 2024. |
|---|
|
|
S18-3. Does the cooperation not make a goal? Reconsider a problem, the wall of ... current situation for possible medicine medicine cooperation of the patients contribution; is ... to medicine medicine cooperation Next Stage 伊藤剛貴 Journal of Japanese Society of Pharmaceutical Oncology 36: 98-98, 2024. |
|---|
|
|
S18-4. Is the cooperation difficult? As ... specialty medical institution cooperation drugstore thinking about the obstacle that regional alliances have ... 久田健登 Journal of Japanese Society of Pharmaceutical Oncology 36: 99-99, 2024. |
|---|
|
|
S18-5. The cancer treatment support of the health insurance pharmacy in the local inclusion care system and at-home cooperation 村田勇人 Journal of Japanese Society of Pharmaceutical Oncology 36: 100-100, 2024. |
|---|
|
|
Symposium 19. Than next generation upbringing - organizer carrying creation and the next generation of the evidence by the collaboration of clinical settings and university ... 河添仁, 土屋雅美 Journal of Japanese Society of Pharmaceutical Oncology 36: 101-101, 2024. |
|---|
|
|
S19-1. Is it the graduate school where you do for what? The prospects of the distance and the study until Doctoral degree course in member of society completion 土屋雅美 Journal of Japanese Society of Pharmaceutical Oncology 36: 102-102, 2024. |
|---|
|
|
S19-2. Student, hospital pharmacist, thought of experience and next generation upbringing to a teacher 杉富行 Journal of Japanese Society of Pharmaceutical Oncology 36: 103-103, 2024. |
|---|
|
|
S19-3. Looking back at the process of a retrospective observational study being published in an overseas academic journal 山崎朋子 Journal of Japanese Society of Pharmaceutical Oncology 36: 104-104, 2024. |
|---|
|
|
S19-4. Upbringing of the pharmacist carrying the next generation when we had study mind and clinical mind 高橋克之 Journal of Japanese Society of Pharmaceutical Oncology 36: 105-105, 2024. |
|---|
|
|
Symposium 20. Than achievement - organizer after a roadmap and the acquisition until APACC/BPACC qualification ... 櫻井洋臣, 縄田修一 Journal of Japanese Society of Pharmaceutical Oncology 36: 106-106, 2024. |
|---|
|
|
S20-1. System summary of authorization, the specialized pharmacist in Japanese clinical tumor Pharmaceutical Society 櫻井洋臣 Journal of Japanese Society of Pharmaceutical Oncology 36: 107-107, 2024. |
|---|
|
|
S20-2. Form, how to convey case report 中島寿久 Journal of Japanese Society of Pharmaceutical Oncology 36: 108-108, 2024. |
|---|
|
|
S20-3. Swing return marks of a submission example and the interview of the pharmaceutical intervention 下川友香理 Journal of Japanese Society of Pharmaceutical Oncology 36: 109-109, 2024. |
|---|
|
|
S20-4. We tell him/her about charm of the cancer practice hospital cooperation training! 縄田修一 Journal of Japanese Society of Pharmaceutical Oncology 36: 110-110, 2024. |
|---|
|
|
S20-5. Point during the cancer practice hospital cooperation training 衛藤智章 Journal of Japanese Society of Pharmaceutical Oncology 36: 111-111, 2024. |
|---|
|
|
S20-6. Achievement as the pharmacist specialized in foreign cancer treatment 山崎友里絵 Journal of Japanese Society of Pharmaceutical Oncology 36: 112-112, 2024. |
|---|
|
|
Symposium 21. Than clinical question - organizer in the elderly people cancer medical treatment ... 鈴木賢一 Journal of Japanese Society of Pharmaceutical Oncology 36: 113-113, 2024. |
|---|
|
|
S21-1. Problems (from a system, a viewpoint of the medical economy) to surround elderly people cancer medical treatment 清水久範 Journal of Japanese Society of Pharmaceutical Oncology 36: 114-114, 2024. |
|---|
|
|
S21-2. Positioning and usage of elderly people usability test (GA) in the cancer medical treatment 市村丈典1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 115-115, 2024. |
|---|
|
|
S21-3. Evidence of the cost effectiveness in the elderly people cancer medical treatment 田中弘人 Journal of Japanese Society of Pharmaceutical Oncology 36: 116-116, 2024. |
|---|
|
|
S21-4. Significance of the health-related quality of life measurement in the elderly people cancer medical therapy 辻将成 Journal of Japanese Society of Pharmaceutical Oncology 36: 117-117, 2024. |
|---|
|
|
S21-5. Evidence of the cancer supportive care in elderly people 鈴木賢一 Journal of Japanese Society of Pharmaceutical Oncology 36: 118-118, 2024. |
|---|
|
|
Symposium 22. The leap of the young pharmacist in strategic next generation upbringing and next generation than contribution - organizer to cancer medical care ...! 小林一男, 藤宮龍祥 Journal of Japanese Society of Pharmaceutical Oncology 36: 119-119, 2024. |
|---|
|
|
S22-1. Innovative approach of charm and next generation upbringing of the multicenter interchange 越智良明 Journal of Japanese Society of Pharmaceutical Oncology 36: 120-120, 2024. |
|---|
|
|
S22-2. Search of the career path, innovative strategy of a variety of choices and next generation upbringings 平田一耕1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 121-121, 2024. |
|---|
|
|
S22-3. A challenge to cancer treatment of the young pharmacist, graduate school entering further education and the prospects of there 畠山織江 Journal of Japanese Society of Pharmaceutical Oncology 36: 122-122, 2024. |
|---|
|
|
S22-4. Young successful example as the leader of cancer treatment in the small and medium size hospital 草野淳一 Journal of Japanese Society of Pharmaceutical Oncology 36: 123-123, 2024. |
|---|
|
|
S22-5. Multi-organization collaborative investigation of the standard development to work on in young people 藤宮龍祥 Journal of Japanese Society of Pharmaceutical Oncology 36: 124-124, 2024. |
|---|
|
|
Symposium 23. How are all? Cancer treatment of patients with dementia. Than decision making and support - organizer to treatment whom a pharmacist has ... 中山季昭, 太田愛子 Journal of Japanese Society of Pharmaceutical Oncology 36: 125-125, 2024. |
|---|
|
|
S23-1. The remedial problem in patients with cancer of dementia and the support that is expected 小川朝生1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 126-126, 2024. |
|---|
|
|
S23-2. With the effect that dementia gives for cancer treatment 藤田行代志 Journal of Japanese Society of Pharmaceutical Oncology 36: 127-127, 2024. |
|---|
|
|
S23-3. Support and problem to patients with dementia cancer in the drugstore 小林圭輔 Journal of Japanese Society of Pharmaceutical Oncology 36: 128-128, 2024. |
|---|
|
|
S23-4. The side effect management of the foreign chemotherapy in patients with old cancer with the cognitive dysfunction 東加奈子 Journal of Japanese Society of Pharmaceutical Oncology 36: 129-129, 2024. |
|---|
|
|
Symposium 24. How do you manage the regimen that continues increasing? Than importance - organizer of the regimen management that fixed its eyes on ... medicine medicine cooperation ... 小谷野大地, 立澤明 Journal of Japanese Society of Pharmaceutical Oncology 36: 130-130, 2024. |
|---|
|
|
S24-1. From the situation of invention - university hospital of the regimen management utilizing the regimen order system - 橋詰淳哉 Journal of Japanese Society of Pharmaceutical Oncology 36: 131-131, 2024. |
|---|
|
|
S24-2. Rare cancer, regimen management and operation of intractable cancer 高野淳 Journal of Japanese Society of Pharmaceutical Oncology 36: 132-132, 2024. |
|---|
|
|
S24-3. To support "regimen management" with the local whole 花香淳一 Journal of Japanese Society of Pharmaceutical Oncology 36: 133-133, 2024. |
|---|
|
|
S24-4. About inflection of the regimen information in the health insurance pharmacy 水井亮 Journal of Japanese Society of Pharmaceutical Oncology 36: 134-134, 2024. |
|---|
|
|
For the promotion of the specialized medical institution cooperation drugstore than a viewpoint of ... administration ... 太田美紀 Journal of Japanese Society of Pharmaceutical Oncology 36: 136-136, 2024. |
|---|
|
|
Based on the current situation of change - specialty medical institution cooperation drugstore of the consciousness of subjects by the foreign cancer treatment (authorization, specialty) pharmacist qualification and the duties environment - 濃沼政美 Journal of Japanese Society of Pharmaceutical Oncology 36: 137-137, 2024. |
|---|
|
|
OA-1. Effect of the proton pump inhibitor combination on effectiveness of the CDK4/6 inhibitor: Look at the multi-organization combination rear; a mark observational study 北洞美佳1), 魚住龍史2), 高橋佳織3), 向原徹4), 林田哲5), 岩部翠6), 飯原大稔1), 河添仁3), 楠原佳那子7), 永山愛子5), 土屋雅美6), 丹羽好美8), 中村智徳3), 小坂真吉9), 二村学8), 関朋子5), 大貫幸二10), 鈴木昭夫1) Journal of Japanese Society of Pharmaceutical Oncology 36: 138-138, 2024. |
|---|
|
|
OA-2. Usefulness of electronic patient-reported outcome in the patients receiving the immune checkpoint inhibitor: Tendency score matching analysis 桂英之1), 太田浩1), 戸井ひとみ1), 池末裕明2), 高田直子1) Journal of Japanese Society of Pharmaceutical Oncology 36: 139-139, 2024. |
|---|
|
|
OA-3. The effect that the telephone follow-up by the health insurance pharmacy pharmacist gives to the prescription of patients receiving injection anticancer medicine 中村俊貴1,2), 爲我井一統1), 坂本岳志1), 境美智順1), 木村雅彦1), 平山武司2,3) Journal of Japanese Society of Pharmaceutical Oncology 36: 140-140, 2024. |
|---|
|
|
OA-4. The effect that cancer cachexia gives to blood poison characteristics of the mFOLFIRINOX therapy and treatment continuance 白尾祐樹, 守田和憲, 山下愛子, 山下園加, 市川洋一, 田上治美 Journal of Japanese Society of Pharmaceutical Oncology 36: 141-141, 2024. |
|---|
|
|
OA-5. Search of the effect predictor of the anamorelin in the cancer cachexia patients 武仲桃子1), 岩田崇2), 竹内知子3), 原なおり3), 加藤涼子4), 小園友明4), 安永ちはる5), 伊藤真理5), 松田真弓6), 春日井悠司4), 林良亮4), 水谷有希1), 坂口達馬6), 山本英督7), 久保昭仁2), 森真治6), 築山郁人1,4,8) Journal of Japanese Society of Pharmaceutical Oncology 36: 142-142, 2024. |
|---|
|
|
OA-6. Direct hospital admission of emergency incidence investigation - stomach cancer, pancreatic cancer in the multiple cancers species using the treatment with anticancer medicine front evaluation, difference - for the breast cancer 中村匡志1), 根本真記1,2), 清水久範1), 青山剛1), 磯松華3), 小島萌葉3), 蓮見萌3), 平出誠3), 鈴木賢一4), 佐野元彦3), 山口正和1), 山本豊2) Journal of Japanese Society of Pharmaceutical Oncology 36: 143-143, 2024. |
|---|
|
|
OA-7. Estimation ... of the medical economic effect based on benefit evaluation - pharmaceutical intervention example of the specialized medical institution cooperation drugstore (cancer) using Poisson regression models 植竹友輔 Journal of Japanese Society of Pharmaceutical Oncology 36: 144-144, 2024. |
|---|
|
|
OA-8. Usefulness of the medicine for patients with old cancer medicine cooperation follow-up based on the elderly people usability test simple tool G8 市村丈典1,2), 村田勇人3), 木村祐子1,2), 徳永愛美1,2), 菅美佳4), 稲垣貴士1,2), 日向美羽1,2), 永田未希1,2), 石井俊一1,2), 小野航太郎1,2), 山口智亮1,2), 市原絢子3), 櫻井彩乃3), 市倉大輔1,2), 宮原克明5), 縄田修一1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 145-145, 2024. |
|---|
|
|
OA-9. Enforcement report of breast cancer enlightenment exercise "using" palpation model that we actually work on at a health insurance pharmacy 瀬戸基樹1), 大江真子1), 中村真理2), 川上真由子3), 中村雅洋4), 堅田陽介4) Journal of Japanese Society of Pharmaceutical Oncology 36: 146-146, 2024. |
|---|
|
|
OA-10. Role of information literacy and the pharmacist of the patients in the examination for oncogene panel 畠山織江1,4), 野尻宗子2), 朝倉弘太1), 小柴聖史1), 齊藤有希1), 岩川悟3), 木村利美1), 加藤俊介4) Journal of Japanese Society of Pharmaceutical Oncology 36: 147-147, 2024. |
|---|
|
|
O-01. A case which was improved by proton pump inhibitor cancellation for hypomagnesemia during panitumumab administration 宮本康敬1), 外山未来1), 平野公美1), 八木貴彦1), 大和千穂1), 野木村藍1), 中村拓哉1), 栗山茂2) Journal of Japanese Society of Pharmaceutical Oncology 36: 148-148, 2024. |
|---|
|
|
O-02. Dermatopathy case of the antiEGFR antibody medicine which used an affected part photograph for pharmaceutical intervention 米良千春1), 山崎ちひろ2), 濱崎まや2), 宮田広樹3) Journal of Japanese Society of Pharmaceutical Oncology 36: 149-149, 2024. |
|---|
|
|
O-03. One patient who presented with nephrotic syndrome during hepatocellular carcinoma Atezolizumab+Bevacizumab therapy 守田和憲, 白尾祐樹, 市川洋一, 山下園加, 山下愛子, 田上治美 Journal of Japanese Society of Pharmaceutical Oncology 36: 150-150, 2024. |
|---|
|
|
O-04. 2 cases that presented a liver damage with the Nivolumab+SOX combination therapy 沢仁美1,3), 平安奈美子2), 岸下陽子2), 中村暢彦4) Journal of Japanese Society of Pharmaceutical Oncology 36: 151-151, 2024. |
|---|
|
|
O-05. A case which produced tubulointerstitial nephritis during nivolumab administration 塚本名奈子, 永井詩織, 岩切悦子, 辰己晃造, 本田富得 Journal of Japanese Society of Pharmaceutical Oncology 36: 152-152, 2024. |
|---|
|
|
O-06. A case which can continue for a long term by a pharmacist having intervened in the patients who started Atezolizumab + bevacizumab therapy for a hepatocellular carcinoma 青木洸英, 佐々木茂樹, 金井詩織, 杉田和夫 Journal of Japanese Society of Pharmaceutical Oncology 36: 153-153, 2024. |
|---|
|
|
O-07. A case which was given Cetuximab+Encorafenib+Binimetinib therapy using the simple suspension method 南有里1), 左右田和枝1), 貝沼潤1), 齋藤雅俊1), 長谷川麻衣2), 西村賢3), 平山武司1,4) Journal of Japanese Society of Pharmaceutical Oncology 36: 154-154, 2024. |
|---|
|
|
O-08. Effect of the pain-killer on effectiveness and safety of the nivolumab in patients with progress gastric cancer 折本彬1), 出町健2) Journal of Japanese Society of Pharmaceutical Oncology 36: 155-155, 2024. |
|---|
|
|
O-09. Presence or absence of irAE onset in the gastric cancer Nivolumab therapy and prognostic correlation 鈴木貴之1), 中山季昭1), 武井大輔1), 松坂和正1), 安部智哉1), 岡田大地1), 直井美萌1), 角坂惟生1), 花井誠1), 原浩樹2), 大塚公庸1) Journal of Japanese Society of Pharmaceutical Oncology 36: 156-156, 2024. |
|---|
|
|
O-10. Investigation of the patients comming to hospital situation in the nivolumab and Pembrolizumab dosage interval extension regimen 浅野裕紀1), 多賀小枝子1), 守屋昭宏1), 竹中翔也1), 伊藤大輔1), 岩井美奈1,2), 木村美智男1,2), 吉村知哲2), 宇佐美英績1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 157-157, 2024. |
|---|
|
|
O-11. About a relationship of Nivolumab therapy and the dermatopathy 濱武清範1), 松田ちひろ1), 野間敏也1), 橋本仁美1), 奥村優介1), 兼行佑奈1), 松本弘誠1), 仲忠士1), 美和孝之1), 小島一晃1), 北英夫2), 神田直樹3) Journal of Japanese Society of Pharmaceutical Oncology 36: 158-158, 2024. |
|---|
|
|
O-12. The use situation of the Pembrolizumab + Lenvatinib combination therapy in the Masuda Red Cross hospital 吉田勝好, 田原明子, 郷原学 Journal of Japanese Society of Pharmaceutical Oncology 36: 159-159, 2024. |
|---|
|
|
O-13. Examination about the association of ICI administration and PD-1 Myopathy in the patients with the antiAChR antibody 五十嵐貴之1), 谷口洋2), 西脇嘉一3), 香取美津治3), 島田惇司1), 泉澤友宏1), 伊藤やす江1), 長谷川英雄1) Journal of Japanese Society of Pharmaceutical Oncology 36: 160-160, 2024. |
|---|
|
|
O-14. Development and evaluation of the cooperation documentation system in the foreign cancer chemotherapy cooperation full addition 牧原明秀, 近藤舞子, 三屋良太, 高原悠子, 鈴木雅人, 吉田弘樹, 木全司 Journal of Japanese Society of Pharmaceutical Oncology 36: 161-161, 2024. |
|---|
|
|
O-15. Examination of the usefulness of the anticancer agent preparation inspection using the web meeting tool 向井光一朗, 東久美子, 村本慎悟 Journal of Japanese Society of Pharmaceutical Oncology 36: 162-162, 2024. |
|---|
|
|
O-16. Study on tendency to expression of cancer classification irAE using the large-scale side effect report database 竹森飛翔, 奥中真白, 手代木貴宏, 加納大輔, 川崎敏克 Journal of Japanese Society of Pharmaceutical Oncology 36: 163-163, 2024. |
|---|
|
|
O-17. Malfunction and preparation, effect to occur at the anticancer medicine preparation using the closed system anesthesia drug transportation system on management 石川大介, 茂木佳子, 阿部桂子 Journal of Japanese Society of Pharmaceutical Oncology 36: 164-164, 2024. |
|---|
|
|
O-18. Relation of the pharmacist in the examination for oncogene panel of our hospital 仲田浩成1,2), 衛藤智章2), 藤田強記2), 清水裕彰2) Journal of Japanese Society of Pharmaceutical Oncology 36: 165-165, 2024. |
|---|
|
|
O-19. Investigation of the anxiety that a new face pharmacist feels for anticancer agent-treated patients and the effect that the lecture by the specialized pharmacist gives 柘植雅大1), 佐藤裕美2), 浅井雅浩2) Journal of Japanese Society of Pharmaceutical Oncology 36: 166-166, 2024. |
|---|
|
|
O-20. One case that suspected phlebothrombus of lower extremities embolism to home medical treatment management patients with prostate cancer of the hormonal therapies average that instructed it 永田雅史1), 藤田あゆみ2), 杉浦伸哉2) Journal of Japanese Society of Pharmaceutical Oncology 36: 167-167, 2024. |
|---|
|
|
O-21. The effect that the intervention of the pharmacist gives to treatment continuation in the foreign cancer chemotherapy 岡崎秀太, 永井大地, 小森由理子, 高橋一栄 Journal of Japanese Society of Pharmaceutical Oncology 36: 168-168, 2024. |
|---|
|
|
O-22. An authorized person can do it for attitude survey - authorized continuation of the pharmacist of the specialized medical institution cooperation drugstore duty 安斎沙織 Journal of Japanese Society of Pharmaceutical Oncology 36: 169-169, 2024. |
|---|
|
|
O-23. Efforts for the education effect inspection of the cancer domain in the local Ro Tate type pharmacist resident program 稲毛慶子1), 溝口由梨香1), 浮谷聡2), 田内紀子3), 緑川はる香3), 瀬戸弘和3), 大谷俊裕2), 枦秀樹1) Journal of Japanese Society of Pharmaceutical Oncology 36: 170-170, 2024. |
|---|
|
|
O-24. The efforts of the foreign cancer instruction workshop and the future prospects 梅谷亮介, 鏡味真依子, 津崎秀斗, 八代哲也, 小牟田豊 Journal of Japanese Society of Pharmaceutical Oncology 36: 171-171, 2024. |
|---|
|
|
O-25. Took advantage of the Web meeting between group institutions; and support to the authorized pharmacist acquisition in the institution 辻本朗1), 小湊彩佳2), 永渕学3) Journal of Japanese Society of Pharmaceutical Oncology 36: 172-172, 2024. |
|---|
|
|
O-26. Examination about the effect that the continuation of the workshop that collaborated with a local health insurance drugstore gave to an adjuvant chemotherapy successful execution rate after the colon cancer technique 飯田遼, 白井真理子, 猪瀬成史, 椿浩之 Journal of Japanese Society of Pharmaceutical Oncology 36: 173-173, 2024. |
|---|
|
|
O-27. A plan and administration of the person in charge of cancer business Web conference between groups 永渕学1), 出口幾文2), 井無田優3), 辻本朗4), 田代一成5), 河野泰明6), 小湊彩佳7), 南佐知子8), 植山寛9) Journal of Japanese Society of Pharmaceutical Oncology 36: 174-174, 2024. |
|---|
|
|
O-28. Effect of the medicine medicine cooperation training about the telephone follow-up of the cancer medical therapy 川田史朗, 山崎美沙都, 東垂水裕和, 西海敬太, 大倉志織, 香川恭子, 小串興平 Journal of Japanese Society of Pharmaceutical Oncology 36: 175-175, 2024. |
|---|
|
|
O-29. Survey on the occurrence of chemotherapy-induced nausea and vomiting after the introduction of fosnetupitant at our hospital 遠藤秀竜, 加藤貴由, 中島彩子, 見尾谷昇, 山崎崇 Journal of Japanese Society of Pharmaceutical Oncology 36: 176-176, 2024. |
|---|
|
|
O-30. A case which presented neutropenia during Olaparib + bevacizumab therapy using a rem decibuilding 永井大地1), 西村美智子1), 岡崎秀太1), 越田裕一郎2), 金本巨万2), 高橋一栄1) Journal of Japanese Society of Pharmaceutical Oncology 36: 177-177, 2024. |
|---|
|
|
O-31. One case that was given it by gradual dose titration for the non-small cell lung cancer which developed drug-related interstitial pneumonia after BRAF/MEK inhibitor administration again 永田泰大1), 鳥居良太1), 湯村真沙子2), 金城和美2), 下雅意彩1) Journal of Japanese Society of Pharmaceutical Oncology 36: 178-178, 2024. |
|---|
|
|
O-32. Examination about the prophylaxis of infusion reaction by Avelumab 斉藤諒1), 梅原健吾1), 高田慎也1), 山岸佳代1), 高田徳容2), 丸山覚2), 原林透2), 橋下浩紀1) Journal of Japanese Society of Pharmaceutical Oncology 36: 179-179, 2024. |
|---|
|
|
O-33. A case which conducted correspondence of the paronychia by an online follow-up for patients with dysarthria 吉川麻里子1), 鈴木大介2) Journal of Japanese Society of Pharmaceutical Oncology 36: 180-180, 2024. |
|---|
|
|
O-34. The current situation investigation about the chemotherapy of the elderly people malignant lymphoma older than 80 years old in our hospital 矢吹剛1), 南場信人1), 関口陽子1), 貝瀬眞由美2) Journal of Japanese Society of Pharmaceutical Oncology 36: 181-181, 2024. |
|---|
|
|
O-35. A case of patients with breast cancer connected by the cooperation with the hospital in direct hospital admission of emergency from discovery of the febrile neutropenia by telephone consultation 許鍵1), 山口智江2), 荒川正悟2), 水谷哲之3), 鈴木大介4) Journal of Japanese Society of Pharmaceutical Oncology 36: 182-182, 2024. |
|---|
|
|
O-36. Fact-finding study of the factor to disturb the prescription suggestion by the medicine medicine cooperation in the cancer chemotherapy 小川純明1,11), 杉本智哉2,11), 地引勝3,11), 村上仁志4,11), 中村敏史5,11), 井上裕貴6,11), 山口智江7,11), 佐々木俊則8,11), 佐藤由美子9,11), 堀田和男10,11), 宮崎雅之1,11) Journal of Japanese Society of Pharmaceutical Oncology 36: 183-183, 2024. |
|---|
|
|
O-37. Fact-finding of the anticancer medicine prescription meeting a demand for health insurance pharmacy pharmacists 佐野綾乃, 福岡俊宏, 松本淳子, 大木健史 Journal of Japanese Society of Pharmaceutical Oncology 36: 184-184, 2024. |
|---|
|
|
O-38. Examination of the factor affecting the instruction to patient of the drugstore pharmacist in the foreign cancer treatment reporting book 丸田勇樹1), 酒井理恵1), 菊池俊裕1), 中西正人2) Journal of Japanese Society of Pharmaceutical Oncology 36: 185-185, 2024. |
|---|
|
|
O-39. Efforts and report about the immune-mediated adverse event early detection with the immune checkpoint inhibitor for the malignant neoplasm 新森健太郎1), 中野知哉2), 一林三保子3), 井上博輝4), 今中宥季1), 松本公佑1), 野口大歌1), 中辻正人5) Journal of Japanese Society of Pharmaceutical Oncology 36: 186-186, 2024. |
|---|
|
|
O-40. Examination about the timing of the telephone follow-up in anticancer medicine-treated patients 田中智枝 Journal of Japanese Society of Pharmaceutical Oncology 36: 187-187, 2024. |
|---|
|
|
O-41. Treatment strategy of unresectable progression recurrent gastric cancer first treatment 富田雅子1), 松岡宏2), 水野智博3), 中内雅也2), 田中毅2), 柴崎晋2), 林高弘1), 須田康一2) Journal of Japanese Society of Pharmaceutical Oncology 36: 188-188, 2024. |
|---|
|
|
O-42. Relationship between venetoclax traf concentration and serum CRP level in patients with acute myeloid leukemia 丸藤義翔1), 安武夫1,2), 城田幹夫2,3), 小林真之2,4) Journal of Japanese Society of Pharmaceutical Oncology 36: 189-189, 2024. |
|---|
|
|
O-43. We look at the rear of the factor influencing effect of treatment of the anamorelin hydrochloride and study a mark search 増野貴司1), 中山和彦1), 黒澤瑛里1), 上田由紀1), 櫻井望1), 服部龍太郎1), 塩野智則2), 高山仁美2), 岩崎英久1), 櫻澤千世1), 長嶺歩3), 大林恭子3), 堀口裕之1) Journal of Japanese Society of Pharmaceutical Oncology 36: 190-190, 2024. |
|---|
|
|
O-44. Nanoliposomal irinotecan and the effectiveness in the parallel administration of the levofolinate, safe evaluation 坂本達彦1), 齋藤佳敬2), 渡辺拓也1), 内山数貴1), 武隈洋1), 小松嘉人3), 菅原満1,4) Journal of Japanese Society of Pharmaceutical Oncology 36: 191-191, 2024. |
|---|
|
|
O-45. Use experience of the dose-dense MVAC therapy for the bladder cancer in the Kyoto Municipal Hospital 大野恵一1), 成瀬圭1), 本多伸二1), 堤尚史2), 小野勝1) Journal of Japanese Society of Pharmaceutical Oncology 36: 192-192, 2024. |
|---|
|
|
O-46. Adverse event survey of Venetoclax - What is the impact on continued use? - 土橋侑介, 阿部雪妃, 小林貴志, 嶋倉みどり, 福田大介, 渡部学 Journal of Japanese Society of Pharmaceutical Oncology 36: 193-193, 2024. |
|---|
|
|
O-47. The effectiveness of the trifluridine/Tipiracil + bevacizumab every other week administration regimen for progress colon cancer, examination about the safe and treatment-related days 竹田あかね1), 井上裕貴2), 近藤健3), 加藤恭子4), 竹田伸3), 末永雅也3), 伊藤武5), 山下克也5), 片岡政人3), 平野隆司2), 北川智余恵4), 吉田知由1) Journal of Japanese Society of Pharmaceutical Oncology 36: 194-194, 2024. |
|---|
|
|
O-48. Survey on pomalidomide-related skin disorders and risk factor analysis 杉富行1,3), 串亮太2), 花井誉3), 萩原政夫4) Journal of Japanese Society of Pharmaceutical Oncology 36: 195-195, 2024. |
|---|
|
|
O-49. Fact-finding of the pharmaceutical intervention with the tracing report in the foreign cancer chemotherapy 柴このみ, 大神正宏, 立原茂樹, 島田浩和, 小島友恵, 鈴木美加 Journal of Japanese Society of Pharmaceutical Oncology 36: 196-196, 2024. |
|---|
|
|
O-50. The current situation and problem of the medicine medicine cooperation in our hospital 鷲足ひろみ, 宮本俊一, 穂積実柚 Journal of Japanese Society of Pharmaceutical Oncology 36: 197-197, 2024. |
|---|
|
|
O-51. Evaluation of the medicine medicine cooperation through the online tracing report 村地康, 金原千明, 高垣佳史 Journal of Japanese Society of Pharmaceutical Oncology 36: 198-198, 2024. |
|---|
|
|
O-52. Change of the medicine medicine cooperation found through the operation of "the cooperation letter between foreign chemotherapy institutions" in the cooperation full addition calculation 山本圭恵, 松井諒, 北野美鈴, 加藤諭美, 山口瑞彦 Journal of Japanese Society of Pharmaceutical Oncology 36: 199-199, 2024. |
|---|
|
|
O-53. It is patients questionary survey about making it it the cooperation improvement of medical institution and health drugstore using "a reporting book of our hospital about the treatment with anticancer medicine to an outpatient" 楠原馬見新佳那子, 栗原昌也, 瀬戸裕美子, 川澄賢司, 松井礼子, 川崎敏克 Journal of Japanese Society of Pharmaceutical Oncology 36: 200-200, 2024. |
|---|
|
|
O-54. Effect (the first report) that brushing up and the cooperation full addition of the cooperation tool give to the number of patients follow-ups 加藤良隆, 川島裕明, 大坪達弥, 友金幹視 Journal of Japanese Society of Pharmaceutical Oncology 36: 201-201, 2024. |
|---|
|
|
O-55. Questionary survey for the improvement in quality of the tracing report report in the efforts of the cooperation full addition 鈴木春子, 楠浩子, 谷健太郎, 荒義昭 Journal of Japanese Society of Pharmaceutical Oncology 36: 202-202, 2024. |
|---|
|
|
O-56. Attitude survey for the medicine medicine cooperation to be concerned with patients with inspection of the usefulness of "the S one remedy start contact vote" and foreign cancer chemotherapy enforcement 渡邉記祥, 神雅昭, 大平尚武, 三上順子, 岡崎圭佑, 中村文博, 早狩亮 Journal of Japanese Society of Pharmaceutical Oncology 36: 203-203, 2024. |
|---|
|
|
O-57. About an approach of the cooperation full addition 山田剛 Journal of Japanese Society of Pharmaceutical Oncology 36: 204-204, 2024. |
|---|
|
|
O-58. Research about the onset of retching, vomiting after the cisplatin administration in patients with juvenile malignant bone soft part tumor 副島梓1), 橋本幸輝1), 川上和宜1), 鈴木亘1), 青山剛1), 阿江啓介2), 山口正和1) Journal of Japanese Society of Pharmaceutical Oncology 36: 205-205, 2024. |
|---|
|
|
O-59. The effectiveness of the olanzapine combination antiemesis therapy for retching, vomiting of patients with multiple myeloma to be given ASCT combination L-PAM massive dose therapy 加藤淳平1), 立田真也1), 吉見猛1), 石田耕太1), 塚田信弘2), 石田禎夫2), 細谷治1) Journal of Japanese Society of Pharmaceutical Oncology 36: 206-206, 2024. |
|---|
|
|
O-60. The retching, vomiting expression situation investigation after the antiemetic change of the gemcitabine + oil xanthan gum (R) therapy 頼光翔, 山田弓美, 村上彩子, 園山智宏, 安食健一, 横手克樹 Journal of Japanese Society of Pharmaceutical Oncology 36: 207-207, 2024. |
|---|
|
|
O-61. The current situation investigation of antiemesis therapy and retching, the vomiting expression situation in the use of Trastuzumab Deruxtecan patients 重村明香, 長谷川拓也, 坂本靖宜, 宇山佳奈, 小泉宏史, 清水絢子, 井出和男, 小池博文, 佐橋幸子 Journal of Japanese Society of Pharmaceutical Oncology 36: 208-208, 2024. |
|---|
|
|
O-62. A meta-analysis about the effectiveness, the safety of 2.5 mg - 10 mg of olanzapine in CINV and systematic review 内野里香, 渋谷悠真 Journal of Japanese Society of Pharmaceutical Oncology 36: 209-209, 2024. |
|---|
|
|
O-63. Efficacy evaluation of fosnetupitant in lung cancer patients at our hospital 國方梨乃, 安宅希美子, 新村航, 住吉健太, 篠原尚樹, 元木貴大, 田中裕章, 小坂信二 Journal of Japanese Society of Pharmaceutical Oncology 36: 210-210, 2024. |
|---|
|
|
O-64. Protective efficacy of CINV (chemotherapy-induced nausea and vomiting) for the patients who lost weight to 2.5 mg after the olanzapine 5 mg remedy and safe examination 下村一景, 前田章光, 橋本直弥, 内田幸作 Journal of Japanese Society of Pharmaceutical Oncology 36: 211-211, 2024. |
|---|
|
|
O-65. Survey on the efficacy and safety of fosnetupitant in cancer chemotherapy 長尾嘉真, 小川千晶, 工藤彰, 大栗宝子, 大塚健太郎, 長山佳之, 今村有那, 石嶋麗, 大塚知信 Journal of Japanese Society of Pharmaceutical Oncology 36: 212-212, 2024. |
|---|
|
|
O-66. A comparison of the injection site reaction frequency in the use of intravenous NK1 receptor blocker: Look at the rear with the single institution; a mark cohort study 基村佳世, 槙原克也, 沖礼子, 木本大樹, 福井梨乃, 松村友和 Journal of Japanese Society of Pharmaceutical Oncology 36: 213-213, 2024. |
|---|
|
|
O-67. Multicenter observational study about the effectiveness, the safety of the antihistamine for Infusion-Related Reaction at the daratumumab subcutaneous injection 鈴川真由1), 鈴木訓史2), 葉山達也3), 藤田行代志4), 谷川大夢5), 小澤有輝6), 末廣直哉7), 鷲巣晋作3), 雨笠愛実8), 新井隆広4), 鈴木洋平5), 井澤美苗9), 望月眞弓9), 清宮啓介9), 石川春樹7), 青森達1,7,9,10), 大谷壽一1,7,9,10) Journal of Japanese Society of Pharmaceutical Oncology 36: 214-214, 2024. |
|---|
|
|
O-68. See the rear about the second generation antihistamine which is drug allergy preventive preparation in the cancer medical therapy; a mark investigation 柿本秀樹1), 大倉野将広2), 長郷あかね2,3), 福江悠香1), 吹上勇真1), 川田哲史2), 真島宏太2), 角康隆2), 井上竜一2), 五十嵐保陽2), 内山将伸2,4), 宮崎元康1,3), 兼重晋2), 緒方憲太郎2,3), 神村英利2,3), 今給黎修1,3) Journal of Japanese Society of Pharmaceutical Oncology 36: 215-215, 2024. |
|---|
|
|
O-69. Fact-finding of the infusion-related reaction expression at the Pola-BR introduction 粂哲雄1), 原田翔平1), 徳武和馬1), 松山円2), 深谷真史3), 吉嗣加奈子3), 式郁恵3), 榎並輝和3), 篠道弘1), 池田宇次3) Journal of Japanese Society of Pharmaceutical Oncology 36: 216-216, 2024. |
|---|
|
|
O-70. About the expression of Infusion reaction situation accompanied with intravenous feeding time for ramucirumab shortening in our hospital 深水勇伍, 仲内純, 花香淳一 Journal of Japanese Society of Pharmaceutical Oncology 36: 217-217, 2024. |
|---|
|
|
PA-01. The association that developed in capecitabine treated patients between hand-and-foot syndrome and external environment: Pilot study 内田敬1), 林克剛1), 土屋雅美1), 岩指元2), 猪岡京子1) Journal of Japanese Society of Pharmaceutical Oncology 36: 218-218, 2024. |
|---|
|
|
PA-02. Multicenter investigation about the immune-mediated adverse event and predictor with the checkpoint inhibitor + platinum combination therapy to non-small cell lung cancer of immunity 久松大祐1), 藤本愛理2), 大窪典子3), 上村豪4), 鈴木寛人5), 大津貴寛6), 大岩根良太7), 谷本憲哉8) Journal of Japanese Society of Pharmaceutical Oncology 36: 219-219, 2024. |
|---|
|
|
PA-03. Effect of concomitant azole antifungal therapy on venetoclax blood concentrations 甲斐絢香1), 萩原政夫2), 杉富行1,3) Journal of Japanese Society of Pharmaceutical Oncology 36: 220-220, 2024. |
|---|
|
|
PA-04. One case that steroid withdrawal syndrome during the G-CHOP therapy enforcement in the follicular lymphoma was suspected in a specialized medical institution cooperation drugstore, and suggested appropriate correspondence 本村真悟 Journal of Japanese Society of Pharmaceutical Oncology 36: 221-221, 2024. |
|---|
|
|
PA-05. The case that blood trough level of tacrolimus increased by tolvaptan combination after the HLA half agreement allograft 土谷裕貴, 藤本冬佳, 森田龍也, 倉橋基尚 Journal of Japanese Society of Pharmaceutical Oncology 36: 222-222, 2024. |
|---|
|
|
PA-06. Questionnaire evaluation of a physician, the nurse about the bringing medicine prescription representation based on the protocol by the pharmacist 山端悠介1), 橋本幸輝1), 小林一男1), 平岡知子1), 米山美里1), 川上和宜1), 井上有香2), 上野貴之2), 矢野智之3), 山口正和1) Journal of Japanese Society of Pharmaceutical Oncology 36: 223-223, 2024. |
|---|
|
|
PA-07. Health-related quality of life ... of patients with health-related quality of life measurement - cancer of the outpatient taking the high-risk medicine by the drugstore pharmacist 辻将成1), 市村丈典2), 村田勇人3), 橋本幸輝4), 鈴木賢一5), 月岡良太6), 清水久範4) Journal of Japanese Society of Pharmaceutical Oncology 36: 224-224, 2024. |
|---|
|
|
PA-08. Patients with cancer to think about from questionary survey expect it of hospital pharmacist 杉本充弘1), 米澤淳1,2), 池見泰明1), 幾田慧子1), 岡田浩3,4), 眞中章弘5), 長縄華子1), 西郷雅美子1), 小川晃宏6), 飯原大稔7), 三宅知宏6), 鈴木昭夫7), 寺田智祐1) Journal of Japanese Society of Pharmaceutical Oncology 36: 225-225, 2024. |
|---|
|
|
P-001. Survey of interstitial pneumonia caused by trastuzumab deruxtecan in our hospital and criteria for testing 田中雅宏, 藤原有紀子, 志田剛一, 小野春菜, 山田航, 吉田友和 Journal of Japanese Society of Pharmaceutical Oncology 36: 226-226, 2024. |
|---|
|
|
P-002. Investigation into the current status of tixagevimab/cilgavimab administration in patients with hematological malignancies and its efficacy in preventing COVID-19 onset 木原星衣, 海野祥生, 生田和之, 高木淳也, 前田美紀, 鹿間友絵, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 36: 227-227, 2024. |
|---|
|
|
P-003. Examination of incidence and the risk factor of retching vomiting in the slight emetic risk drug Olaparib 石原達弥1), 平田一耕2,3), 松本優太1), 舟越亮寛3,4) Journal of Japanese Society of Pharmaceutical Oncology 36: 228-228, 2024. |
|---|
|
|
P-004. About operation after development and the introduction of the apothecaries measure indication system 西畑友尋1), 村井望1), 十亀將輝1), 新居田能章1), 末廣拓1), 宇都本孝夫1), 松岡葉子1), 織田高子1), 玉井宏一1), 池内靖恵2), 山下広恵2), 烏谷政和1), 倉田知久1) Journal of Japanese Society of Pharmaceutical Oncology 36: 229-229, 2024. |
|---|
|
|
P-005. The effect that the side effect disease severity of the tyrosine kinase inhibitor in the chronic myelogenous leukemia gives for a molecular genetic response 鷲巣晋作1,3), 葉山達也1,3), 内池明博1,3), 坪井伸也1,3), 長木弓子1,3), 宮城愛1,3), 矢萩温子1), 三浦勝浩2,3), 大塚進1) Journal of Japanese Society of Pharmaceutical Oncology 36: 230-230, 2024. |
|---|
|
|
P-006. Appropriate use of trastuzumab deruxtecan based on the hospital manual 松窪美花1), 山田充宏1), 山田聖浩1), 太崎恵1), 高濱啓太1), 中野正啓2), 藤末真実子2), 大佐古智文2) Journal of Japanese Society of Pharmaceutical Oncology 36: 231-231, 2024. |
|---|
|
|
P-007. The use situation investigation of olanzapine for the prevention of chemotherapy-induced retching, vomiting in our hospital 竹内健人, 和田祐一, 小西喜明, 鈴木美世利, 谷口賢二 Journal of Japanese Society of Pharmaceutical Oncology 36: 232-232, 2024. |
|---|
|
|
P-008. Examination of the effect on cancer pain predictor of tramadol 深澤真実1), 高武嘉道1), 藤本愛理2), 中原萌子1), 鶴山萌子1), 三好孝法1), 山口泰弘1), 川俣洋生3), 花田聖典4), 橋本雅司1) Journal of Japanese Society of Pharmaceutical Oncology 36: 233-233, 2024. |
|---|
|
|
P-009. Examination about the effect of the oxaliplatin vascular pain measures protocol 西井拓人1), 中川貴弘1), 北庄司敦久1), 中川直樹1), 烏野隆博1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 234-234, 2024. |
|---|
|
|
P-010. The oral prostate cancer therapeutic drug handling situation in the health insurance pharmacy 照屋千津子, 野々原育子, 土橋美和 Journal of Japanese Society of Pharmaceutical Oncology 36: 235-235, 2024. |
|---|
|
|
P-011. Search of the relations of a side effect and the use dose of the regorafenib 成瀬安優1), 岩田崇2), 三嶋秀行3), 佐久間晶基4), 竹内正幸4), 大西正文4), 池田義明1), 柳澤聖5), 築山郁人5) Journal of Japanese Society of Pharmaceutical Oncology 36: 236-236, 2024. |
|---|
|
|
P-012. The enforcement situation of the Lenvatinib Pembrolizumab therapy (endometrial cancer) 合津貴志1), 渡部照美1), 佐々木美里1), 関根悠1), 渡邉紘章1), 久保田真生1), 加藤千絵1), 築地洸大1), 松崎安也奈1), 橋本歳洋2), 田崎政則1) Journal of Japanese Society of Pharmaceutical Oncology 36: 237-237, 2024. |
|---|
|
|
P-013. Drug economic assessment of the ICI combination chemotherapy in the extensive-stage small cell lung cancer 森下拓哉, 山田桃子, 田代匠, 宮澤憲治, 高木亮 Journal of Japanese Society of Pharmaceutical Oncology 36: 238-238, 2024. |
|---|
|
|
P-014. Investigation about the Durvalumab maintenance therapy after the non-small cell lung cancer chemoradiotherapy 小竹正晃1), 坂井由紀1), 渡部聡2), 外山聡1) Journal of Japanese Society of Pharmaceutical Oncology 36: 239-239, 2024. |
|---|
|
|
P-015. The operation of the Gee raster subcutaneous injection body pod and the evaluation 外山未来1), 宮本康敬1), 平野公美1), 八木貴彦1), 大和千穂1), 野木村藍1), 中村拓哉1), 重野一幸2) Journal of Japanese Society of Pharmaceutical Oncology 36: 240-240, 2024. |
|---|
|
|
P-016. Investigation of use situation and irAE of ICI for the primary treatment of unresectable progress, recurrent esophageal cancer 橋口麻依子, 藤田強記, 後藤隆, 清水裕彰 Journal of Japanese Society of Pharmaceutical Oncology 36: 241-241, 2024. |
|---|
|
|
P-017. A survey of the rate of complete suppression of emesis (CR rate) in patients using fosnetupitant with or without olanzapine concomitant use 三柳心路, 谷垣雄都, 松岡智美, 前原大輔, 寺崎展幸, 本間久美子 Journal of Japanese Society of Pharmaceutical Oncology 36: 242-242, 2024. |
|---|
|
|
P-018. Analysis of the factor about adoption of the prescription suggestion in the tracing report 門田悠佑, 佐野孝光, 中村美波理 Journal of Japanese Society of Pharmaceutical Oncology 36: 243-243, 2024. |
|---|
|
|
P-019. Fact-finding of the irAE onset in patients receiving immune checkpoint inhibitor 眞崎晃1), 宮崎元康2,3), 柿本秀樹2), 吹上勇真2), 福江悠香2), 今給黎修2,3) Journal of Japanese Society of Pharmaceutical Oncology 36: 244-244, 2024. |
|---|
|
|
P-020. Effect to diarrhea inhibition of the ramosetron hydrochloride on patients receiving Abemaciclib 尾形美絵, 近藤和宏, 羽生智宏, 新関みどり, 長澤欣弘, 瀧内瑛輔, 中村慎太郎, 田村和彦 Journal of Japanese Society of Pharmaceutical Oncology 36: 245-245, 2024. |
|---|
|
|
P-021. Efforts of our drugstore for irAE early detection 高木正信1,2), 上田麻未4), 佐藤萌3), 孫世庚4), 富田真由3), 赤嶺美奈1,2), 赤嶺有希子2), 田中祥子1,2), 加納美知子1,2), 久野木良子1,2), 堀泰羽1,2), 松尾律子1,2), 姜恵元1,2), 平野陽子1,2), 吉原澄吉5), 谷田弘5), 澤井一1) Journal of Japanese Society of Pharmaceutical Oncology 36: 246-246, 2024. |
|---|
|
|
P-022. The drug instruction system to foreign cancer chemotherapy patients in our hospital 原田真由美, 市川卓哉, 益子里美 Journal of Japanese Society of Pharmaceutical Oncology 36: 247-247, 2024. |
|---|
|
|
P-023. Examination about the effectiveness and the safety of the Ipi+Nivo combination therapy for malignant pleural mesothelioma (MPM) 高取俊和, 高田星羅, 沖田健太郎, 船越幸代 Journal of Japanese Society of Pharmaceutical Oncology 36: 248-248, 2024. |
|---|
|
|
P-024. Basic investigation about the 5-HT3 receptor blocker of the supportive care steroid spare ring for the cancer chemotherapy in patients with digestive organ cancer 新井聡子, 大井田紗希, 村上明男, 濱野愛里, 安森奈緒子, 軍司剛宏 Journal of Japanese Society of Pharmaceutical Oncology 36: 249-249, 2024. |
|---|
|
|
P-025. Effect of the infusion increase in quantity on vascular pain at the oxaliplatin periphery intravenous administration 河村勇介1), 山根実里1), 妹尾啓司1), 岡原夏実1), 水上皓喜1), 石田翔1), 吉川明良2), 阪田安彦3), 宮森伸一3), 渡邊篤1) Journal of Japanese Society of Pharmaceutical Oncology 36: 250-250, 2024. |
|---|
|
|
P-026. Predictive precision of the Teicoplanin blood level at febrile neutropenia onset in patients with blood tumor 瀧川正紀1), 田中博之2), 諏訪淳一3), 島崎良知4), 小野田稔久2), 石井敏浩2) Journal of Japanese Society of Pharmaceutical Oncology 36: 251-251, 2024. |
|---|
|
|
P-027. Relative investigation with the oral mucositis onset of the cancer chemotherapy patients by the retrospective study and disease severity and the blood test value 古賀雅良1), 吉田謙介1), 黒川亮2), 星野直人1), 齋藤千愛1), 田中恵子2), 石山茉佑佳2), 曽我麻理恵2), 山下萌2), 金丸博子2), 朴慶純3), 冨原圭4), 外山聡1) Journal of Japanese Society of Pharmaceutical Oncology 36: 252-252, 2024. |
|---|
|
|
P-028. Comparison between mannitol and protective efficacy of furosemide for the cisplatin-induced renal failure 張光雄大1), 林稔展1), 三好孝法2), 山下朱莉1), 津曲恭一3), 横田千明4), 江川孝1) Journal of Japanese Society of Pharmaceutical Oncology 36: 253-253, 2024. |
|---|
|
|
P-029. The side effect expression situation of the Polatuzumab vedotin combination chemotherapy in the true clinical practice 三浦千里, 土屋雅美, 江沼圭一, 猪岡京子 Journal of Japanese Society of Pharmaceutical Oncology 36: 254-254, 2024. |
|---|
|
|
P-030. Effect of the continuous pharmacist intervention on patients in the checkpoint inhibitor administration of immunity 河野茉里子, 伊平正樹, 鈴木富紀子, 谷本美幸, 會田秀明, 恩田佳奈, 保屋野貴通 Journal of Japanese Society of Pharmaceutical Oncology 36: 255-255, 2024. |
|---|
|
|
P-031. Analysis and evaluation of the pharmaceutical intervention of the pharmacist to patients with foreign cancer chemotherapy enforcement 三上忠司, 桑村恒夫, 中川義浩 Journal of Japanese Society of Pharmaceutical Oncology 36: 256-256, 2024. |
|---|
|
|
P-032. Examination ... about the relationship of use situation - PD-L1 frequencies and the effect of the Durvalumab in our hospital 佐藤康, 竹野裕晶, 穂苅慎, 金子睦志, 近藤宏 Journal of Japanese Society of Pharmaceutical Oncology 36: 257-257, 2024. |
|---|
|
|
P-033. Search of the onset of Colin symptom situation and the background factor of patients who received Modified FOLFIRINOX 久枝真一郎, 宗広樹 Journal of Japanese Society of Pharmaceutical Oncology 36: 258-258, 2024. |
|---|
|
|
P-034. The use results and the side effect expression situation of our hospital of chemotherapy and the nivolumab combination therapy in gastric cancer first treatment 石田晶子, 古田裕幸, 窪田悠希, 米田詩織, 荒谷恭子, 前田裕行 Journal of Japanese Society of Pharmaceutical Oncology 36: 259-259, 2024. |
|---|
|
|
P-035. Survey on the actual use of fosnetupitant after its introduction in cancer chemotherapy 江原美里, 砂田萌, 松本健吾, 田中麻理子, 竹松茂樹, 福田利明 Journal of Japanese Society of Pharmaceutical Oncology 36: 260-260, 2024. |
|---|
|
|
P-036. Comparative study of the antiemetic effects of fosnetupitant and aprepitant, including delayed and late emetic effects, at our hospital 鈴木雅人, 吉田弘樹, 渡邊ちひろ, 吉見彩香, 安藤武志, 近藤舞子, 三屋良太, 牧原明秀, 高原悠子, 木全司 Journal of Japanese Society of Pharmaceutical Oncology 36: 261-261, 2024. |
|---|
|
|
P-037. About the course after introduction and the operation of Gee raster subcutaneous injection 3.6 mg body pod (R) 井上咲紀1), 佐藤浩二1), 植田真理1), 小久保祐希1), 島田敏江2), 浅井真由美2), 香川雅一1,4), 西岡達也1), 藤田淳也2,3), 吉野知子5) Journal of Japanese Society of Pharmaceutical Oncology 36: 262-262, 2024. |
|---|
|
|
P-038. Fact-finding of the use situation and the adverse event of the Pola-R-CHP therapy for untreated DLBCL 豊田えり, 山本普子, 眞壁秀樹 Journal of Japanese Society of Pharmaceutical Oncology 36: 263-263, 2024. |
|---|
|
|
P-039. Association between effect of treatment and intensity of treatment and dose in the cancer of the esophagus DCF therapy 江崎佳奈恵, 上瀧喬仁, 二又陽香, 唐川聖司, 内田沙織, 高橋誠, 樋口恭子 Journal of Japanese Society of Pharmaceutical Oncology 36: 264-264, 2024. |
|---|
|
|
P-040. Investigation into the duration of pimitespib administration and adverse events in patients with imatinib-resistant gastrointestinal stromal tumors 酒井悠華, 山田晏菜 Journal of Japanese Society of Pharmaceutical Oncology 36: 265-265, 2024. |
|---|
|
|
P-041. The use situation investigation of the sotorasib in the Himeji medical center 田中麻理子, 江原美里, 砂田萌, 松本健吾, 竹松茂樹, 福田利明 Journal of Japanese Society of Pharmaceutical Oncology 36: 266-266, 2024. |
|---|
|
|
P-042. Comparison of the antiemesis effect of dexamethasone single dose and the 4th administration on the late start period retching vomiting with the slight emetic risk chemotherapy 山下朱莉, 林稔展, 張光雄大, 江川孝 Journal of Japanese Society of Pharmaceutical Oncology 36: 267-267, 2024. |
|---|
|
|
P-043. Examination about the angiopathic risk factor in the FEC (60/100) therapy 松田亜莉沙1), 相場裕美子1), 吉岡我佳命1), 鎌田順道2), 田澤賢一3), 日野浩司2) Journal of Japanese Society of Pharmaceutical Oncology 36: 268-268, 2024. |
|---|
|
|
P-044. The introduction of fosnetupitant and its impact on outpatient side effect control 高畑雅臣1), 松岡佳吾1), 奥ヶ谷教1), 久米央子1), 山本伸洋2), 亀谷朋子2), 笹木有佑3) Journal of Japanese Society of Pharmaceutical Oncology 36: 269-269, 2024. |
|---|
|
|
P-045. The use situation investigation of the tepotinib hydrochloride hydrate 砂田萌, 田中麻理子, 江原美里, 松本健吾, 竹松茂樹, 福田利明 Journal of Japanese Society of Pharmaceutical Oncology 36: 270-270, 2024. |
|---|
|
|
P-046. Search of the risk factor of the Oxaliplatin-related vascular pain 寺舘圭祐1), 前田健太1), 板谷眞理恵1), 星貴薫2) Journal of Japanese Society of Pharmaceutical Oncology 36: 271-271, 2024. |
|---|
|
|
P-047. Examination about the use actual situation of the clinical features in a cancer and patients with diagnosed venous thromboembolism and the anticancer medicine 岡田貴裕1), 須永登美子1), 縄田修一1), 礒良崇2), 江波戸美緒2), 土至田勉2), 鈴木洋2), 向後麻里3) Journal of Japanese Society of Pharmaceutical Oncology 36: 272-272, 2024. |
|---|
|
|
P-048. Onset of dermatopathy by the panitumumab in patients with colon cancer and hypomagnesemia and relative examination of the effect of treatment 小林柊太1), 平井成和2), 有山智博1,3), 真坂亙1), 増田雅行1) Journal of Japanese Society of Pharmaceutical Oncology 36: 273-273, 2024. |
|---|
|
|
P-049. Examination of the drug instruction contents for the use of immune checkpoint inhibitor patients 中村俊之1), 久保田理恵1), 西増春佳1), 大岡千寿子1), 野洌孝二1), 小室太郎2) Journal of Japanese Society of Pharmaceutical Oncology 36: 274-274, 2024. |
|---|
|
|
P-050. The use situation and side effect expression investigation of the Olaparib for patients with ovarian cancer in our hospital 町田梨絵子, 田中早穂子, 原友子, 野中敏治 Journal of Japanese Society of Pharmaceutical Oncology 36: 275-275, 2024. |
|---|
|
|
P-051. Development of plasma Axitinib assay using the HPLC-UV method 平賀建1), 丸山真一1), 加藤大2), 菅野浩1) Journal of Japanese Society of Pharmaceutical Oncology 36: 276-276, 2024. |
|---|
|
|
P-052. Elucidation of the factor influencing the anamorelin treatment continuance in patients of the cancer cachexia 五十嵐遥1), 藤田一馬1), 福司弥生1), 赤嶺由美子1), 佐々木克也1), 柴田浩行2) Journal of Japanese Society of Pharmaceutical Oncology 36: 277-277, 2024. |
|---|
|
|
P-053. Examination of the multi-type of job intervention effect in the anamorelin administration on stomach, colon cancer of elderly people 福泉智子1), 久松大祐2), 西嶋智洋3,4), 後藤隆2), 清水裕彰2), 高田正温1) Journal of Japanese Society of Pharmaceutical Oncology 36: 278-278, 2024. |
|---|
|
|
P-054. Effect by the bendamustine rate of application change in our hospital 平池美香子, 松藤敬佑, 馬場結子, 齋藤巨樹, 小園亜希, 湊本康則 Journal of Japanese Society of Pharmaceutical Oncology 36: 279-279, 2024. |
|---|
|
|
P-055. Role of the glycemic control situation and the pharmacist by the diabetologist at the pancreatic cancer chemotherapy 石嶋麗, 小川千晶, 武重彩子, 工藤彰, 長尾嘉真, 長山佳之, 大塚健太郎, 大栗宝子, 今村有那, 大塚知信 Journal of Japanese Society of Pharmaceutical Oncology 36: 280-280, 2024. |
|---|
|
|
P-056. Actual status survey on the safety of trastuzumab deruxtecan therapy for HER2-positive inoperable or recurrent breast cancer at our hospital 前田祐香, 清水裕章, 衛藤智章, 樋口文子, 原茉梨絵 Journal of Japanese Society of Pharmaceutical Oncology 36: 281-281, 2024. |
|---|
|
|
P-057. Relationship between enfortumab vedotin-induced skin disorders and immune checkpoint inhibitors 松藤敬佑, 平池美香子, 馬場結子, 斎藤巨樹, 小園亜希, 湊本康則 Journal of Japanese Society of Pharmaceutical Oncology 36: 282-282, 2024. |
|---|
|
|
P-058. Investigation of the usefulness for the patients response before the medical examination of the pharmacist for physicians 松井礼子1,2), 川上和宜1,3), 高橋郷1,4), 川崎敏克1,2), 山口正和1,3), 遠藤一司1,5), 近藤直樹1,6) Journal of Japanese Society of Pharmaceutical Oncology 36: 283-283, 2024. |
|---|
|
|
P-059. The onset situation of the adrenal crisis in patients with adrenal insufficiency by the immune-mediated adverse event 新井隆広, 井上千菜美, 藤田行代志, 齊藤妙子 Journal of Japanese Society of Pharmaceutical Oncology 36: 284-284, 2024. |
|---|
|
|
P-060. The introduction example that was useful when it adopted it as hospital preparation to consider the correspondence to the item which became the wall at use of Mohs paste 岸本真1), 米田仁保1), 池沢若菜1), 徳永楓果1), 北園幸大1), 田中恭人1), 森永崇史1), 中村杏果1), 石渡美樹1), 栗田泰樹1), 上野菜巳1), 上野怜良1), 前田裕太1), 屋敷大輔1), 淵脇ゆかり1), 徳丸章佳1), 長ヶ原琢磨1), 荻尾夕起子1), 濱田琴巳2) Journal of Japanese Society of Pharmaceutical Oncology 36: 285-285, 2024. |
|---|
|
|
P-061. Efficacy and adverse events of fosnetupitant - After switching from aprepitant and fosaprepitant - 藤木健行 Journal of Japanese Society of Pharmaceutical Oncology 36: 286-286, 2024. |
|---|
|
|
P-062. Efforts of our hospital for the purpose of the early detection of the immune-mediated adverse event at the checkpoint inhibitor administration of immunity 窪田奈々, 岡田侑子, 山室明子, 霍間ひろの, 池田美咲, 佐藤大輔 Journal of Japanese Society of Pharmaceutical Oncology 36: 287-287, 2024. |
|---|
|
|
P-063. Consideration of the characteristic of the capecitabine internal use patients whom a hand-and-foot syndrome does not develop in 氏木里依子, 内藤千秋, 平野友也 Journal of Japanese Society of Pharmaceutical Oncology 36: 288-288, 2024. |
|---|
|
|
P-064. The intensity of treatment of the therapy with Obinutuzumab for the untreated follicular lymphoma or rituximab and bendamustine and safe comparison 田中亜弥1), 原茉梨絵1), 衛藤智章1), 宮下要2), 立川義倫2), 崔日承2), 末廣陽子2), 杉本理恵3), 清水裕彰1) Journal of Japanese Society of Pharmaceutical Oncology 36: 289-289, 2024. |
|---|
|
|
P-065. Report about the effect that the weight loss of VEN doses in the VEN+AZA therapy gives 川崎健一, 中川雅史, 泉本裕美, 宮内実奈絵, 毛利萌, 岸本一希, 上田祥子, 樫葉利人 Journal of Japanese Society of Pharmaceutical Oncology 36: 290-290, 2024. |
|---|
|
|
P-066. Examination about the proteinuria exacerbation risk in ramucirumab treated patients 吉年勉, 杉野可那子, 石川麻子, 下寺美帆子, 米光涼, 中川早百合, 粕淵一顕, 梅永真弓 Journal of Japanese Society of Pharmaceutical Oncology 36: 291-291, 2024. |
|---|
|
|
P-067. Study on change over time of Serious Adverse Event accompanied with the development of the treatment with oral anticancer medicine (2020 report) 古岡桃果, 川澄賢司, 田中将貴, 末永亘, 松井礼子, 川崎敏克 Journal of Japanese Society of Pharmaceutical Oncology 36: 292-292, 2024. |
|---|
|
|
P-068. A pain change accompanied with the switching to the diclofenac sodium percutaneous absorption type preparation in the use of oral, transvenous transrectal NSAIDs patients and investigation of the use situation 早川美妃1), 五十嵐隆志1), 中村真穂1), 熊澤名穂子1), 三浦智史2) Journal of Japanese Society of Pharmaceutical Oncology 36: 293-293, 2024. |
|---|
|
|
P-069. Usability questionary survey of Gee raster body pod (R) 河原陽介, 大嶋舞, 鈴木藍, 加藤良治 Journal of Japanese Society of Pharmaceutical Oncology 36: 294-294, 2024. |
|---|
|
|
P-070. The immune-mediated adverse event management to think about from the pharmacist outpatient department 高橋大1), 佐々木悠稀1), 佐藤和文1), 濱田圭之輔1), 熊谷敏宏1), 駒木裕一2), 加藤博孝3), 高橋康介1) Journal of Japanese Society of Pharmaceutical Oncology 36: 295-295, 2024. |
|---|
|
|
P-071. Evaluation of effect and the telephone consultation that a corona evil gives to perioperative breast cancer chemotherapy 武笠隼人, 川田亮, 小島菜緒 Journal of Japanese Society of Pharmaceutical Oncology 36: 296-296, 2024. |
|---|
|
|
P-072. Evaluation of the use and efficacy of fosnetupitant in combination regimens with oxaliplatin and irinotecan for colorectal cancer (first report) 庄司美侑1,2), 田中弘人1,2), 井ノ口岳洋1,2), 久保村優1,2), 吉川聡美1), 村上美聖1,2), 輪湖哲也1,2), 伊勢雄也1), 笠原寿郎2) Journal of Japanese Society of Pharmaceutical Oncology 36: 297-297, 2024. |
|---|
|
|
P-073. Efforts for application in the true clinical practice of cancer chemotherapy side effect management application and the efficiency of the side effect management 安部圭紀, 辻茉莉香, 溝口明子, 塚川麻利子, 佐藤弘子, 五十嵐文, 高橋賢成 Journal of Japanese Society of Pharmaceutical Oncology 36: 298-298, 2024. |
|---|
|
|
P-074. Fact-finding of the steroid therapy for the immune-mediated adverse event with the immune checkpoint inhibitor 河西貴絵, 藤原愛美, 高橋佳祐, 冨田真理, 都村勇樹, 松成菜穂子, 近藤沙菜, 白石貴寿 Journal of Japanese Society of Pharmaceutical Oncology 36: 299-299, 2024. |
|---|
|
|
P-075. Experience of the lenalidomide + rituximab combination therapy 清水幸宏1), 堀内俊克1), 坂本真菜美2), 坂西亜由美2), 佐藤裕之2) Journal of Japanese Society of Pharmaceutical Oncology 36: 300-300, 2024. |
|---|
|
|
P-076. An effect of the anamorelin and examination about the introduction time 木村萌美1), 大神正宏2), 小島寛3), 鈴木美加2) Journal of Japanese Society of Pharmaceutical Oncology 36: 301-301, 2024. |
|---|
|
|
P-077. The onset of febrile neutropenia situation investigation that we compared before and after a corona outbreak in the foreign chemotherapy 中島優子, 石川夏波, 黒川俊光, 加納亜由子, 野澤彰 Journal of Japanese Society of Pharmaceutical Oncology 36: 302-302, 2024. |
|---|
|
|
P-078. Operation in the aluminum Knox treatment introduction in the citizen comprehensive medical care center attached to Yokohama City University and report of the efforts 虫明美紀, 山口智子, 宇野洋司, 津野丈彦, 小杉三弥子, 佐橋幸子 Journal of Japanese Society of Pharmaceutical Oncology 36: 303-303, 2024. |
|---|
|
|
P-079. Investigation about the effect that a dose gives to effect of treatment at start of therapy of the trifluridine Tipiracil 稲田佑亮, 京谷充崇, 山下敦志 Journal of Japanese Society of Pharmaceutical Oncology 36: 304-304, 2024. |
|---|
|
|
P-080. Investigation of adverse events in trastuzumab deruxtecan therapy 遠藤美央, 玉木慎也 Journal of Japanese Society of Pharmaceutical Oncology 36: 305-305, 2024. |
|---|
|
|
P-081. Effect of the concomitant drug giving it to the onset of the hypomagnesemia by the panitumumab 羽鳥真由1), 勝見重昭1,2), 八島秀明2), 長井桃子1), 柴崎由実1), 荒木拓也1,2), 山本康次郎1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 306-306, 2024. |
|---|
|
|
P-082. We weigh it against d- chlorpheniramine in the paclitaxel administration about the protective efficacy of the allergic reaction of diphenhydramine 村川瑞穂, 二宮優智, 松本拓真, 生田智基, 亀岡春菜, 長谷部匡史, 堀田修次, 森近俊之 Journal of Japanese Society of Pharmaceutical Oncology 36: 307-307, 2024. |
|---|
|
|
P-083. The study that examined the onset of interstitial lung disease situation of patients receiving immune checkpoint inhibitor in the lung cancer medical treatment and the factor 山内雅仁1), 渡邊卓嗣1,2), 飯沼尚己1), 高橋優花1), 塩澤誠1), 鈴木直人1), 有馬遥太朗1), 佐々木高信3), 岡田浩司1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 308-308, 2024. |
|---|
|
|
P-084. Fact-finding of the Durvalumab maintenance therapy after the radical chemoradiation treatment in the non-small cell lung cancer and pharmaceutical intervention 川端貢司1), 芦崎雅之1), 山崎雅久2), 阿部昌宏2), 垂水晋太郎2), 平田力1) Journal of Japanese Society of Pharmaceutical Oncology 36: 309-309, 2024. |
|---|
|
|
P-085. Switching from aprepitant to fosnetupitant and subsequent evaluation 原田典和, 石原瑛太郎, 佐野嘉容子, 片桐将志, 加地努 Journal of Japanese Society of Pharmaceutical Oncology 36: 310-310, 2024. |
|---|
|
|
P-086. The use situation investigation of the peg filgrastim subcutaneous injection body pod preparation in our hospital 佐々木元暉1), 中西大介1), 畑地治2), 牛田浩司1) Journal of Japanese Society of Pharmaceutical Oncology 36: 311-311, 2024. |
|---|
|
|
P-087. About association of the immune-mediated adverse event and effect of treatment with the immune checkpoint inhibitor 松本諭, 堀部正記, 安田智之, 赤石憲俊, 大津佐和子, 辻本純子 Journal of Japanese Society of Pharmaceutical Oncology 36: 312-312, 2024. |
|---|
|
|
P-088. Problem to be found from a use evaluation and the foreign chemotherapy room nurse questionnaire of the patients for the sustained G-CSF preparation automatic administration device 野上佳奈子1), 山内雅仁1), 平川寛之1), 佐藤みほ3), 綱木美由紀3), 岡田浩司1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 313-313, 2024. |
|---|
|
|
P-089. Examination of the effects of planned drug holidays on treatment duration and safety of venetoclax + azacitidine therapy 細井雅史, 大登剛, 土屋裕伴, 新井亘 Journal of Japanese Society of Pharmaceutical Oncology 36: 314-314, 2024. |
|---|
|
|
P-090. Examination of the factor about safety of the Abemaciclib in our hospital 川崎沙織, 大登剛, 齋藤由貴, 土屋裕伴, 新井亘 Journal of Japanese Society of Pharmaceutical Oncology 36: 315-315, 2024. |
|---|
|
|
P-091. Fact-finding about the infection onset of the bendamustine therapy for the untreated low-grade non-Hodgkin's lymphoma 小林美奈子1), 鈴木訓史1), 梅内実穂1), 東敬太1), 木皿重樹2), 内藤義博1) Journal of Japanese Society of Pharmaceutical Oncology 36: 316-316, 2024. |
|---|
|
|
P-092. A study on the evaluation of CINV during preoperative and postoperative ddEC and administration of aprepitant or fosnetupitant during EC therapy in breast cancer patients 向山龍司1), 奥山直門1), 重川崇2), 淺川英輝2), 永川咲子3), 多賀祐香3), 塚越彩夏3), 仲井美由紀3), 山口幸恵3), 河原英子1) Journal of Japanese Society of Pharmaceutical Oncology 36: 317-317, 2024. |
|---|
|
|
P-093. Investigation of the onset of taste disturbance situation for the perioperative chemotherapy of the HER2-positive breast cancer 川島悠吾, 平松英治, 宗本尚子, 村嶋彩加, 岩泉奈央, 松本圭司 Journal of Japanese Society of Pharmaceutical Oncology 36: 318-318, 2024. |
|---|
|
|
P-094. Efforts about introduction of dexrazoxane in the Saitama Medical University country medical center and the inventory control 高山裕樹1), 高山俊輔1), 牧野好倫1), 眞壁秀樹2) Journal of Japanese Society of Pharmaceutical Oncology 36: 319-319, 2024. |
|---|
|
|
P-095. An effect of the mirogabalin on CIPN and investigation of the intervention contents of the pharmacist 中澤紘, 新津京介, 飯田恭子, 平重朋美, 高山美恭, 小澤遼平, 鈴木栄, 長谷部忠史 Journal of Japanese Society of Pharmaceutical Oncology 36: 320-320, 2024. |
|---|
|
|
P-096. The effectiveness for dyspnea of hydromorphone in patients with impaired renal function of our hospital and safe investigation 本間さとみ, 土屋裕伴, 諸橋賢人, 新井亘 Journal of Japanese Society of Pharmaceutical Oncology 36: 321-321, 2024. |
|---|
|
|
P-097. Use fact-finding of the patients who received cisplatin + gemcitabine + Necitumumab combination therapy after the second treatment in the squamous cell carcinoma of lung 初山多恵1), 松下拓夢2), 後藤桂輔1), 片岡優太1), 若本あずさ1), 佐藤秀紀2) Journal of Japanese Society of Pharmaceutical Oncology 36: 322-322, 2024. |
|---|
|
|
P-098. Evaluation of the antiemesis effect of decaDelon for the anthracycline cyclophosphamide combination therapy and olanzapine 生田和之1), 海野祥生1), 吉田達也2), 高木淳也1), 前田美紀1), 木原星衣1), 鹿間友絵1), 深田玲於奈2), 虫明寛行2), 加藤一郎1) Journal of Japanese Society of Pharmaceutical Oncology 36: 323-323, 2024. |
|---|
|
|
P-099. Effect on CINV protective efficacy and medical expenses by the prophylactic antiemetic protocol introduction using the steroid spare ring 田代一成, 江口徹, 西村直寛 Journal of Japanese Society of Pharmaceutical Oncology 36: 324-324, 2024. |
|---|
|
|
P-100. Examination of the development situation of the cytokine-releasing syndrome with the bi-specific antibody molecule preparation and the appropriate management 宮本聖子1), 吉井薫1), 齋藤巨樹2), 小園亜希2), 湊本康則2) Journal of Japanese Society of Pharmaceutical Oncology 36: 325-325, 2024. |
|---|
|
|
P-101. We look at the rear about the usefulness of the local injection for the extravasation of the anticancer medicine and study a mark 湯舟香春1), 小室雅人1), 石川紗衣1), 野々垣彰2), 百武宏志1), 玉木毅2), 西村富啓1) Journal of Japanese Society of Pharmaceutical Oncology 36: 326-326, 2024. |
|---|
|
|
P-102. Fact-finding of the Gee raster (R) body pod preparation introduction 真鍋春希1), 島貫裕実子1), 下村昭彦2), 大橋養賢1), 小室雅人1), 増田純一1), 西村富啓1), 清水千佳子2) Journal of Japanese Society of Pharmaceutical Oncology 36: 327-327, 2024. |
|---|
|
|
P-103. Effect of Rho kinase inhibitor fasudil on paclitaxel-induced peripheral neuropathy 佐藤葵1), 荒井耕太1), 相田和輝1), 杉富行2), 野澤玲子1) Journal of Japanese Society of Pharmaceutical Oncology 36: 328-328, 2024. |
|---|
|
|
P-104. Examination of the effectiveness of a steroid local site injection and the steroid drug for external use application in the leaking skin injury of vincristine in the mouse: Mouse experiment 荒井耕太1), 甲斐絢香1), 野澤 (石井) 玲子2), 杉富行1) Journal of Japanese Society of Pharmaceutical Oncology 36: 329-329, 2024. |
|---|
|
|
P-105. Examination about the telephone consultation from the cancer chemotherapy patients in the foreign chemotherapy room 萩歩美, 組橋由記, 福島ゆかり, 森井聖二 Journal of Japanese Society of Pharmaceutical Oncology 36: 330-330, 2024. |
|---|
|
|
P-106. The nivolumab + ipilimumab therapy for patients with non-small cell lung cancer of ECOG PS 2: Management and two years treatment one case that continued of the liver damage 樋口裕樹1), 三浦麻莉子1), 齋藤幹人2,3), 加藤佳瑞紀4), 今井豊1) Journal of Japanese Society of Pharmaceutical Oncology 36: 331-331, 2024. |
|---|
|
|
P-107. 2 cases that varies in the course until the type I diabetes mellitus onset by immune checkpoint inhibitor (ICI) 佐々木祐太1), 庄野裕志1), 山西香織1), 佐光留美1), 工藤慶太2) Journal of Japanese Society of Pharmaceutical Oncology 36: 332-332, 2024. |
|---|
|
|
P-108. A case of the non-small cell lung cancer which gave cisplatin combination chemotherapy after the hypersensitivity reaction by the Carboplatin, and was effective 永田祐子1), 豊川剛二2), 杉山晃子3), 島松晋一郎2), 齋藤巨樹1), 大久保博史1), 上田仁2) Journal of Japanese Society of Pharmaceutical Oncology 36: 333-333, 2024. |
|---|
|
|
P-109. One case of the Atezolizumab + bevacizumab therapy that led to early detection, treatment of the irAE nephritis in the multi-type of job conference, and came by treatment continuation 小泉綾乃1), 堀之内藍1), 武田さち子3), 早坂夏美4), 菅原彩香4), 木村修2), 田中敏1) Journal of Japanese Society of Pharmaceutical Oncology 36: 334-334, 2024. |
|---|
|
|
P-110. Example of the irAE management using the instruction tool by the health insurance pharmacy pharmacist 足立昇平 Journal of Japanese Society of Pharmaceutical Oncology 36: 335-335, 2024. |
|---|
|
|
P-111. One case that led to the reduction of the adverse event by the follow-up by the drugstore pharmacist for patients with colon cancer of the CAPOX+BV therapy 河端明子, 永田雅史 Journal of Japanese Society of Pharmaceutical Oncology 36: 336-336, 2024. |
|---|
|
|
P-112. A report of two cases of relapsed/refractory adult T-cell leukemia/lymphoma in which treatment was switched from tucidinostat to valemetostat 助畑歩, 中村雄亮, 大野真史, 北川瑚姫, 小森均, 深井敏隆 Journal of Japanese Society of Pharmaceutical Oncology 36: 337-337, 2024. |
|---|
|
|
P-113. Somnolent a case which occurred with oxaliplatin administration 佐藤誠一, 小泉充, 前島光廣 Journal of Japanese Society of Pharmaceutical Oncology 36: 338-338, 2024. |
|---|
|
|
P-114. Investigation of the expression situation and the study implementation situation of the immune-mediated adverse event with the immune checkpoint inhibitor 妹尾真紀子, 山岡香梨, 山崎彩子, ベルトラン陽子, 加賀谷隆彦 Journal of Japanese Society of Pharmaceutical Oncology 36: 339-339, 2024. |
|---|
|
|
P-115. A case that adverse event monitoring by e-PRO led to early detection of drug-related pneumonia of medical therapy patients after the breast cancer technique 川島瑞生1), 徳留雄太1), 武井優輝1), 野本敦文1), 三宅優子1), 義那有彩1), 土屋雅勇1), 光永義治1), 渡部多真紀1,2), 安野伸浩1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 340-340, 2024. |
|---|
|
|
P-116. "To continue internal use of the anamorelin? The actual situation of the anamorelin administration in our hospital" 赤城佳奈, 齊藤直美 Journal of Japanese Society of Pharmaceutical Oncology 36: 341-341, 2024. |
|---|
|
|
P-117. Intervention in the health insurance pharmacy for patients with colon cancer which started FOLFIRI therapy 澤井一1), 宇野遥2), 久世友3), 赤嶺美奈1,4), 赤嶺有希子4), 加納美知子1,4), 久野木良子1), 高木正信1,4), 田中祥子1,4), 堀泰羽1,4), 松尾律子1,4), 姜惠元1), 平野陽子4), 吉原澄吉5), 谷田弘5) Journal of Japanese Society of Pharmaceutical Oncology 36: 342-342, 2024. |
|---|
|
|
P-118. Pharmacological interventions for adverse events of enfortumab vedotin therapy 藤本真規子1), 澤野麻子2), 谷岡洋造1), 武藤達也1) Journal of Japanese Society of Pharmaceutical Oncology 36: 343-343, 2024. |
|---|
|
|
P-119. Two cases in which follow-up after medication instruction led to early detection of adverse events caused by durvalumab and selpercatinib 鈴木麻衣子1), 竜田都加1), 牛田慎二2) Journal of Japanese Society of Pharmaceutical Oncology 36: 344-344, 2024. |
|---|
|
|
P-120. A case of severe bone marrow suppression and febrile neutropenia caused by niraparib 林宏紀, 山本泰大, 福岡智宏, 出口裕子 Journal of Japanese Society of Pharmaceutical Oncology 36: 345-345, 2024. |
|---|
|
|
P-121. Two cases of renal dysfunction after administration of selpercatinib and consideration of concomitant medications 福江悠香1), 柿本秀樹1), 吹上勇真1), 中島章雄1,2), 萩原知佳1), 木下義晃3), 小出容平3), 宮崎元康1,2), 今給黎修1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 346-346, 2024. |
|---|
|
|
P-122. One case that we switched to methylprednisolone for edematous exacerbation during irAE renal failure treatment with the prednisolone, and treatment was able to continue 上柳汐果, 森本健幹, 林洋太郎, 稲田顕慶, 八瀬恵理子, 小田亮介, 丸山直岳, 土井敏行 Journal of Japanese Society of Pharmaceutical Oncology 36: 347-347, 2024. |
|---|
|
|
P-123. Outpatient home therapy with blinatumomab 後藤望 Journal of Japanese Society of Pharmaceutical Oncology 36: 348-348, 2024. |
|---|
|
|
P-124. By having used folic acid and vitamin B12 together during S-1 internal use; a case with suspected side effect reinforcement 川村真理恵, 酒井由希子, 柳田義一 Journal of Japanese Society of Pharmaceutical Oncology 36: 349-349, 2024. |
|---|
|
|
P-125. Case in the early detection of the side effect of the agent anticancer by uniform management of the remedy medicine and formulations juxtaposition type drugstore that was able to cooperate to appropriate treatment 左近美佳, 日置琢斗 Journal of Japanese Society of Pharmaceutical Oncology 36: 350-350, 2024. |
|---|
|
|
P-126. One patient who received intraspinal injection therapy for existing treatment non-small cell lung cancer who had the Ollivier's disease 鈴木実1), 岩上泰崇1), 村田美佳2), 大杉純3) Journal of Japanese Society of Pharmaceutical Oncology 36: 351-351, 2024. |
|---|
|
|
P-127. A case of the black hairy tongue which resulted from minocycline chronic administration for skin lesions by the panitumumab in patients with metastatic colorectal cancer 稲垣貴士1,2), 市村丈典1,2), 市倉大輔1,2), 若村邦彦3), 縄田修一1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 352-352, 2024. |
|---|
|
|
P-128. The case that we were concerned with as a family pharmacist from the diagnosis of patients with lung cancer to treatment, palliative care 西川育子, 平田崇代, 宮崎恵, 森田渚映子, 高井佳江 Journal of Japanese Society of Pharmaceutical Oncology 36: 353-353, 2024. |
|---|
|
|
P-129. 1 case that was relieved by administration in front of butylscopolamine to the patients whom severe Colin symptom developed in for FOLFIRINOX therapy 竹内勉1,2), 矢倉利香2), 片岡優子2), 立山裕美子2), 松浦貴世2), 阪口のり子2), 森利恵2) Journal of Japanese Society of Pharmaceutical Oncology 36: 354-354, 2024. |
|---|
|
|
P-130. One case that patients with colon cancer during haemodialysis received mFOLFOX6 therapy, and resulted in hyperammonemia 小嶋恭平1), 須藤誠2) Journal of Japanese Society of Pharmaceutical Oncology 36: 355-355, 2024. |
|---|
|
|
P-131. A case of the extensive-stage small cell lung cancer that obtained a long-term response by amrubicin therapy under the peg filgrastim combination 鬼丸昌大, 関根旭人, 岩田愛香, 岡野希 Journal of Japanese Society of Pharmaceutical Oncology 36: 356-356, 2024. |
|---|
|
|
P-132. Retching, vomiting expression turn of eventss accompanied with the antiemetic drug switching of the protocol registration for the Carboplatin-containing regimen 渡邊大地1), 舩山悠太郎1), 曽我佳太郎1), 射場晴輝3), 鈴木孝司2) Journal of Japanese Society of Pharmaceutical Oncology 36: 357-357, 2024. |
|---|
|
|
P-133. A case in which dealing with various side effects of enfortumab therapy led to treatment continuation 亀岡貴哉 Journal of Japanese Society of Pharmaceutical Oncology 36: 358-358, 2024. |
|---|
|
|
P-134. 1 case that retching was improved at suggestion of olanzapine in the chemotherapy of the moderate emetic risk, and chemotherapy became the continuation 大野雅斗, 岩瀬裕治, 丹羽直人 Journal of Japanese Society of Pharmaceutical Oncology 36: 359-359, 2024. |
|---|
|
|
P-135. The case that was connected to the fourth treatment by the long-term concordance medical care of the patients with rare cancer (gastrointestinal stromal tumor: a GIST) 赤嶺美奈1), 今井麻理乃4), 赤嶺有希子1), 加納美知子2), 久野木良子2), 高木正信2), 田中祥子1), 堀泰羽1), 松尾律子2), 姜恵元2), 吉原澄吉3), 谷田弘3), 澤井一2) Journal of Japanese Society of Pharmaceutical Oncology 36: 360-360, 2024. |
|---|
|
|
P-136. One case that a drugstore pharmacist intervened in by a telephone follow-up for a diarrhea symptom by the Osimertinib 沼崎香, 鯨明美, 小野恵美子, 丹羽直人 Journal of Japanese Society of Pharmaceutical Oncology 36: 361-361, 2024. |
|---|
|
|
P-137. Two patients whom a serious neutropenia developed in after the dexrazoxane administration 宇山佳奈1), 小泉宏史1), 坂本靖宜1), 清水絢子1), 長谷川拓也1), 井出和男1), 堀田信之2), 小池博文1), 佐橋幸子1) Journal of Japanese Society of Pharmaceutical Oncology 36: 362-362, 2024. |
|---|
|
|
P-138. A case of the TC (docetaxel + cyclophosphamide) therapy before operation for the heart failure merger breast cancer that decreased of left ventricular ejection fraction (LVEF) 太田恵, 香取史菜, 菅野浩 Journal of Japanese Society of Pharmaceutical Oncology 36: 363-363, 2024. |
|---|
|
|
P-139. Use fact-finding of the anamorelin hydrochloride 前田美紀, 海野祥生, 生田和之, 高木淳也, 木原星衣, 鹿間友絵, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 36: 364-364, 2024. |
|---|
|
|
P-140. A case of nausea during intravenous administration of fosnetupitant 金子睦志1), 佐藤康1), 竹野裕晶1), 穂苅慎1), 細川浩輝1), 近藤宏1), 照沼正博2) Journal of Japanese Society of Pharmaceutical Oncology 36: 365-365, 2024. |
|---|
|
|
P-141. It is one patient receiving Tocilizumab for irAE pneumonitis after the Pembrolizumab administration in patients with lung adenocarcinoma 高橋周平, 守田和憲, 徳永晃己, 市川洋一, 山下愛子, 柴田啓智, 田中忠宏, 田上治美 Journal of Japanese Society of Pharmaceutical Oncology 36: 366-366, 2024. |
|---|
|
|
P-142. A case of the hippopotamus diTaki cell treated patients whom peg filgrastim was not able to use for a side effect 井上徹雄, 奥山優希, 鹿島孝子 Journal of Japanese Society of Pharmaceutical Oncology 36: 367-367, 2024. |
|---|
|
|
P-143. A case of the prescription suggestion that used a telephone follow-up and the medication reporting book to the patients who had poor pain control 野田美佳1), 野嶋芳紀1), 齋藤聡夫1), 松尾宗一郎1), 邑瀬誠1), 深津英人2), 松井洸2), 阿部真也2), 山口浩2), 野村和彦2) Journal of Japanese Society of Pharmaceutical Oncology 36: 368-368, 2024. |
|---|
|
|
P-144. Investigation about the effect to give analgesic effect of the opioid preparation in the use of immune checkpoint inhibitor patients 岡田悠加, 佐野隆大, 井上智恵, 西窪奈津子 Journal of Japanese Society of Pharmaceutical Oncology 36: 369-369, 2024. |
|---|
|
|
P-145. One case that the illness medicine cooperation for patients with colon cancer prevented the aggravation of the side effect, and led to treatment continuation 野田佳子, 濱田美輝, 蓑輪圭一郎 Journal of Japanese Society of Pharmaceutical Oncology 36: 370-370, 2024. |
|---|
|
|
P-146. One patient whom dysfunction thyroid and type I diabetes mellitus developed in in irAE by the nivolumab 千吉良幸子, 村松茂代, 西場弘美, 小材直人, 蟻川勝 Journal of Japanese Society of Pharmaceutical Oncology 36: 371-371, 2024. |
|---|
|
|
P-147. A case of fulminant type 1 diabetes mellitus caused by pembrolizumab 石田智之 Journal of Japanese Society of Pharmaceutical Oncology 36: 372-372, 2024. |
|---|
|
|
P-148. 1 case that a pharmacist intervened for patients with breast cancer during the haemodialysis enforcement, and was given EC therapy 加賀麻友美1), 門田佳子1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 373-373, 2024. |
|---|
|
|
P-149. 1 case that was given gemcitabine, combination therapy of the cisplatin for haemodialysis patients of the bladder cancer 森田龍也, 土谷裕貴, 倉橋基尚 Journal of Japanese Society of Pharmaceutical Oncology 36: 374-374, 2024. |
|---|
|
|
P-150. About safety in the bevacizumab Biosimilar administration 石倉遥 Journal of Japanese Society of Pharmaceutical Oncology 36: 375-375, 2024. |
|---|
|
|
P-151. A case which was able to continue lenvatinib, the pembrolizumab combination therapy at the hospital for middle scale acute phase by the participation of the pharmacist 高橋亮治1), 西崎綾乃1), 加藤真由美1), 上田展代1), 小林理章2) Journal of Japanese Society of Pharmaceutical Oncology 36: 376-376, 2024. |
|---|
|
|
P-152. Investigation about the difference between the clinical departments of the adverse event profile in Pembrolizumab + Lenvatinib combination therapy 西村祐香1), 梅原健吾1), 磯場勇輔2), 高田慎也1), 山岸佳代1), 佐藤秀紀2), 見延進一郎3), 原林透4), 橋下浩紀1) Journal of Japanese Society of Pharmaceutical Oncology 36: 377-377, 2024. |
|---|
|
|
P-153. A case which contributed to pain control by the telephone follow-up using the pain diary 松本光司, 川上ありす Journal of Japanese Society of Pharmaceutical Oncology 36: 378-378, 2024. |
|---|
|
|
P-154. A case of introducing combination therapy of polatuzumab vedotin and R-CHP for intravascular lymphoma developed in a hemodialysis patient 岩本大紀1), 平林幸生2), 塩田桃子1), 寳福誠1) Journal of Japanese Society of Pharmaceutical Oncology 36: 379-379, 2024. |
|---|
|
|
P-155. A case that a low Ca blood symptom, a low Mg blood symptom were prolonged after Lenvatinib + Pembrolizumab combination therapy for the cancer of endometrium 犬塚理子1), 丸山真一1), 小笠原あゆみ2), 池原佳世子3), 一城貴政3), 吉田卓功2), 菅野浩1) Journal of Japanese Society of Pharmaceutical Oncology 36: 380-380, 2024. |
|---|
|
|
P-156. Examination about the conversion ratio from parenteral injection of the hydromorphone preparation to an oral formulation 嶋崎広典, 本田一春 Journal of Japanese Society of Pharmaceutical Oncology 36: 381-381, 2024. |
|---|
|
|
P-157. A case that the hiccups that resulted from SOX+Nivo therapy was improved by medicine medicine cooperation 大谷拓輝, 久田健登, 加藤博昭, 阪元清量, 小鷹篤, 飯塚敏美 Journal of Japanese Society of Pharmaceutical Oncology 36: 382-382, 2024. |
|---|
|
|
P-158. Low Mg blood symptom ... with case ... antiEGFR antibody medicine that we were able to contribute to chemotherapy by the drawing blood confirmation at the health insurance pharmacy 川上ありす, 田中翔馬, 松本光司 Journal of Japanese Society of Pharmaceutical Oncology 36: 383-383, 2024. |
|---|
|
|
P-159. A case with suspected skin ulcer by the extravasation at the vinorelbine administration 山田みなみ1), 小井土啓一1), 堀田恵美子2), 松田悟郎3), 長島愛1), 新藤学1) Journal of Japanese Society of Pharmaceutical Oncology 36: 384-384, 2024. |
|---|
|
|
P-160. One case of the dermatopathy to completely succeed by an immune checkpoint inhibitor, and to give it, and to have been completed, but to continue 東湧真1), 橋本竜1,2), 風岡真美1), 吉成宏顕1), 梅田鈴香1), 川島健1), 鈴木直人1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 385-385, 2024. |
|---|
|
|
P-161. One case that noticed the cardiac activity disorder onset during pazopanib remedy by the telephone follow-up that a specialized medical institution cooperation drugstore conducted 斉藤和寛1), 高田慎也2), 梅原健吾2), 橋下浩紀2), 宮田広樹3) Journal of Japanese Society of Pharmaceutical Oncology 36: 386-386, 2024. |
|---|
|
|
P-162. A case which suffered from vascular pain with dacarbazine 小澤遼平, 中澤鉱, 飯田恭子, 高山美恭, 新津京介, 鈴木栄, 長谷部忠史 Journal of Japanese Society of Pharmaceutical Oncology 36: 387-387, 2024. |
|---|
|
|
P-163. It is one patient with suspected taste disturbance after the use of mirogabalin in a chemotherapy-induced peripheral neuropathy improvement purpose 河村航平1), 露木恵梨1), 一柳博美1), 神谷悠紀2) Journal of Japanese Society of Pharmaceutical Oncology 36: 388-388, 2024. |
|---|
|
|
P-164. Treatment management of venetoclax for acute myeloid leukemia at our hospital - An example of neutropenia management - 野口美幸, 椿浩之 Journal of Japanese Society of Pharmaceutical Oncology 36: 389-389, 2024. |
|---|
|
|
P-165. 1 case that was given FOLFIRI-2 for duodenal cancer 戸上博昭1), 永田真里1), 高木彩菜1), 有竹典2), 北川雄一2), 市野貴信1), 川端康次2) Journal of Japanese Society of Pharmaceutical Oncology 36: 390-390, 2024. |
|---|
|
|
P-166. About the role that a drugstore pharmacist should fulfil by team approach in medical care in the foreign chemotherapy 白戸達介1), 市ノ渡真史2), 長谷川佳孝2), 月岡良太2), 大石美也2) Journal of Japanese Society of Pharmaceutical Oncology 36: 391-391, 2024. |
|---|
|
|
P-167. Will of the actual situation of the colon cancer examination consultation encouragement by the drugstore pharmacist and the efforts 廣瀬希海1), 岩田紘樹1,2), 小林典子1,2), 近藤慎吾1,2), 中村友紀1,2), 山浦克典1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 392-392, 2024. |
|---|
|
|
P-168. Examination ... of the usefulness of firmness stock purchase services such as attempt - antitumor agents, and the like of the medicine medicine cooperation in a specialized medical institution cooperation drugstore and the local health insurance pharmacy 立澤明1), 松本剛1), 加藤美奈子2) Journal of Japanese Society of Pharmaceutical Oncology 36: 393-393, 2024. |
|---|
|
|
P-169. About a follow-up of the ethical pharmacy in the foreign chemotherapy and the result 大井優奈, 佐藤翼, 田中栄理加, 小笠原佑介, 竹田敏美, 増井卓也, 藥袋恵太, 遠藤崚平, 高野久美, 染谷光洋 Journal of Japanese Society of Pharmaceutical Oncology 36: 394-394, 2024. |
|---|
|
|
P-170. Fact-finding about formulations of Hazardous Drugs of the insurance pharmacist 齋藤栄1), 荒川亮2), 野田政充3), 堀野忠夫3), 町田充4), 渋谷清1,2), 青木学一1,2), 尾鳥勝也2,5) Journal of Japanese Society of Pharmaceutical Oncology 36: 395-395, 2024. |
|---|
|
|
P-171. About the use situation of closed system anesthesia drug transportation system (CSTD) in our hospital 村上賢志, 倉井岳史, 中丸朗 Journal of Japanese Society of Pharmaceutical Oncology 36: 396-396, 2024. |
|---|
|
|
P-172. Development of the new cleaning method of the preparation work environment using the strong acid-related water to electrolyze in hope of an anticancer medicine decontamination effect 清水久範1), 野々宮悠真1), 大塚優芽1), 谷口愉香1), 石渡幸則2), 岩崎雄介3), 平出誠4), 鈴木賢一5), 山口正和1) Journal of Japanese Society of Pharmaceutical Oncology 36: 397-397, 2024. |
|---|
|
|
P-173. The effect that the cooperation full addition gives to the intervention of the pharmacist and the benefit of patients in the foreign cancer chemotherapy 海野祥生, 高木淳也, 生田和之, 前田美紀, 鹿間友絵, 木原星衣, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 36: 398-398, 2024. |
|---|
|
|
P-174. The usefulness of the neo-shield and workability evaluation 立原茂樹, 大神正宏, 島田浩和, 小島友恵, 柴このみ, 植田清孝, 鈴木美加 Journal of Japanese Society of Pharmaceutical Oncology 36: 399-399, 2024. |
|---|
|
|
P-175. Efforts for the regimen administrative work labor saving 伊勢原祐子, 佐野隆大, 井上智恵, 西窪奈津子 Journal of Japanese Society of Pharmaceutical Oncology 36: 400-400, 2024. |
|---|
|
|
P-176. The occurrence and countermeasures of coring and leakage during preparation of Treakisym R intravenous infusion using Chemosafelock at our hospital 榊原冴香, 羽賀博昭, 上村賢介, 内坪誉歳 Journal of Japanese Society of Pharmaceutical Oncology 36: 401-401, 2024. |
|---|
|
|
P-177. Verification of operational improvement effects by introducing fosnetupitant 延川正雄, 菅原拓也, 齋藤順, 佐東未咲, 杉本拓哉, 松田圭一郎 Journal of Japanese Society of Pharmaceutical Oncology 36: 402-402, 2024. |
|---|
|
|
P-178. Examination of the nature to pass a tube for collapse suspensibility of the oral anticancer medicine by the simple suspension method using the quick bag and the enteral feeding 石川大貴1), 具志堅翔太1), 天野学2), 青木学一3,4), 齋藤栄4), 渋谷清3,4), 時田佳苗3), 武智研志1,5), 高取真吾1,5) Journal of Japanese Society of Pharmaceutical Oncology 36: 403-403, 2024. |
|---|
|
|
P-179. Evaluation of the daily life cleaning effect using the hypochlorous acid water on cyclophosphamide and gemcitabine 増渕敬久, 景秀典, 井野川徹, 榎本英明, 大山將治, 傅恵美, 石丸博雅, 津田泰正, 後藤一美 Journal of Japanese Society of Pharmaceutical Oncology 36: 404-404, 2024. |
|---|
|
|
P-180. Efforts for the disposal reduction after the anticancer agent preparation 岡田優子 Journal of Japanese Society of Pharmaceutical Oncology 36: 405-405, 2024. |
|---|
|
|
P-181. The anticancer agent exposure situation and problems (the second report) after the closed system anesthesia drug transportation system introduction expansion 加藤剛志, 藤井克知, 岩松真理香, 坂口貴大, 斎藤和悦 Journal of Japanese Society of Pharmaceutical Oncology 36: 406-406, 2024. |
|---|
|
|
P-182. Introduction of the weight inspection with the anticancer agent preparation support system 高畑裕1), 上田知秀1), 尾崎仁美1), 今村洋貴1), 大森由紀1), 伊藤博公2) Journal of Japanese Society of Pharmaceutical Oncology 36: 407-407, 2024. |
|---|
|
|
P-183. Reexamination of the item of the enforcement situation and the examination representation input of medical treatment management (PBPM) based on the protocol aiming at early detection of immune-mediated adverse event (irAE) 石田真友子, 三松史野, 大野恵一, 佐分利美帆子, 内藤舞, 本多伸二, 小野勝 Journal of Japanese Society of Pharmaceutical Oncology 36: 408-408, 2024. |
|---|
|
|
P-184. Influence to the anticancer medicine for closed system anesthesia drug transportation system preparation time by the device change 羽田真理子, 殿村直也, 宮澤真帆, 寺山義泰 Journal of Japanese Society of Pharmaceutical Oncology 36: 409-409, 2024. |
|---|
|
|
P-185. Efforts of the acting hepatitis B-related examination input before the chemotherapy enforcement 小澤有輝, 草野淳一, 矢吹優, 春木弥生, 山本龍世, 吉田理, 林誠一 Journal of Japanese Society of Pharmaceutical Oncology 36: 410-410, 2024. |
|---|
|
|
P-186. Efforts of proper use of our hospital for ICI and the safety management 原田優, 橋口宏司, 横山敦, 鈴木葵, 相馬柊子, 佐伯朋哉, 坪井仁美, 中島研 Journal of Japanese Society of Pharmaceutical Oncology 36: 411-411, 2024. |
|---|
|
|
P-187. About the effect that the understock of Augmentin combination tablets gives in the healthcare setting and a change of prescription example 坂本加奈1), 金谷実侑1), 中村侑衣花1), 藤原大一朗2), 野田明宏2), 田邊和史2) Journal of Japanese Society of Pharmaceutical Oncology 36: 412-412, 2024. |
|---|
|
|
P-188. Efforts for the safe injection anticancer agent enforcement in our hospital 野原真吾, 伊東真由子, 永見康男, 中村知子, 政井謙, 東ひかる, 吉山昂佑, 松元大地, 沓野隆太郎, 岡林倫子, 野村遥華, 東ひとみ, 山本和宜 Journal of Japanese Society of Pharmaceutical Oncology 36: 413-413, 2024. |
|---|
|
|
P-189. Periodical anticancer agent exposure environment monitoring in the chemotherapy center and the evaluation 鈴木敦詞1), 加藤翔大1), 新妻憲枝2), 中釜浩美2), 古田美保3), 坂田洋1), 竹内健悟1), 石黒友希1), 鈴木大吾1), 田中伸明1), 中村敏史1), 服部芳明4) Journal of Japanese Society of Pharmaceutical Oncology 36: 414-414, 2024. |
|---|
|
|
P-190. It is evaluated the preparation experience ratio by the change and the preparation efficiency in anticancer agent preparation score list introduction and an anticancer agent preparation maneuver instruction schedule 吉田弘樹, 安田知弘, 吉見彩香, 高木裕介, 牧原明秀, 高原悠子, 天野杏南, 鈴木雅人, 木全司 Journal of Japanese Society of Pharmaceutical Oncology 36: 415-415, 2024. |
|---|
|
|
P-191. Duties examination of a preparation, the administration by closed system anesthesia drug transportation system (CSTD) 山賀亮祐1,2), 菅原裕美1,2), 多田聡子1,2), 佐藤汐莉1,2), 中島美知穂1,2), 慶元箕1,2), 周治由香里1,2), 伊東俊雅1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 416-416, 2024. |
|---|
|
|
P-192. Fact-finding of doubt inquiry in our hospital pharmacist outpatient department 長門亜侑, 川西仁美, 三宅真史, 渡辺麻里子, 監物英男 Journal of Japanese Society of Pharmaceutical Oncology 36: 417-417, 2024. |
|---|
|
|
P-193. An attitude survey for the anticancer agent exposure and examination about the association with the environmental research 菊池良介, 福嶋知樹, 東條汐里, 永井友視, 小林みわ子, 橘田文彦, 鈴木貴明 Journal of Japanese Society of Pharmaceutical Oncology 36: 418-418, 2024. |
|---|
|
|
P-194. Fact-finding of the study implementation situation and the pharmacist intervention about the HBV (HBV) reactivation prevention with the cancer chemotherapy 北村真奈美, 三好康介, 小田怜史, 渡部英明, 景山花奈, 梅田勇一 Journal of Japanese Society of Pharmaceutical Oncology 36: 419-419, 2024. |
|---|
|
|
P-195. About the making of the medication counseling sheet of Abemaciclib tablets in our hospital and future efforts 岩川悟1), 戸田純司1), 高橋信矢1), 大谷拓也1), 細野貴成1), 野津祐貴1), 室岡邦彦1), 岡崎任晴1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 420-420, 2024. |
|---|
|
|
P-196. Effect of the injection drug coinfusion inspection system introduction in anticancer medicine preparation duties 福永晃右, 福迫美保菜, 石田智之, 末永尚輝, 鶴永大貴, 中村有莉恵, 堀内智裕, 赤星真広, 森岡友美, 池増鮎美, 佐多照正 Journal of Japanese Society of Pharmaceutical Oncology 36: 421-421, 2024. |
|---|
|
|
P-197. Construction of the anticancer medicine preparation support system which enabled unification of the information and intuitive operation 高山俊輔, 山崎智香子, 増村雅斗, 津村大地, 三浦聡至, 水野友紀子, 増田裕子, 小谷野大地, 牧野好倫 Journal of Japanese Society of Pharmaceutical Oncology 36: 422-422, 2024. |
|---|
|
|
P-198. Efforts (the second report) for the intervention promotion to foreign cancer instruction to patient of our hospital 畠山卓, 掛札聡美, 飯嶋歩, 小林美佳 Journal of Japanese Society of Pharmaceutical Oncology 36: 423-423, 2024. |
|---|
|
|
P-199. Pharmacist duties in the ePRO introduction for cancer chemotherapy patients and qualitative examination for patients 武井優輝1), 徳留雄太1), 野本敦文1), 川島瑞生1), 三宅優子1), 義那有彩1), 光永義治1), 久保田篤司1,2), 渡部多真紀1,2), 安野伸浩1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 424-424, 2024. |
|---|
|
|
P-201. The pharmaceutical products source of information investigation whom a health insurance pharmacy pharmacist utilizes at foreign cancer medical treatment intervention 原田素子1), 牧原直2), 石川裕規3), 坂口和志4), 荒井元志5), 本村真悟1), 足立昇平6), 正木研7), 本田雅志8), 下川友香理8), 月原健8) Journal of Japanese Society of Pharmaceutical Oncology 36: 425-425, 2024. |
|---|
|
|
P-202. Investigation of the checkpoint inhibitor administration situation of immunity and the immune-mediated adverse event expression situation using a database 畠山智明1), 玉木慎也1), 滝川邦子2), 伊藤勇樹2), 曽我部進3), 小島哲弥3) Journal of Japanese Society of Pharmaceutical Oncology 36: 426-426, 2024. |
|---|
|
|
P-203. Comparison of the adverse event expression situation with the immune checkpoint inhibitor using the adverse drug reaction database 叶拓也, 臼井孝 Journal of Japanese Society of Pharmaceutical Oncology 36: 427-427, 2024. |
|---|
|
|
P-204. Examination about the usefulness of Drug Vial Optimization with the anticancer agent preparation robot 尾田未来, 栗島直希, 津野丈彦, 牛島大介, 小杉三弥子, 佐橋幸子 Journal of Japanese Society of Pharmaceutical Oncology 36: 428-428, 2024. |
|---|
|
|
P-205. Cross-sectional analysis between the drug which paid its attention to mapping of the information on adverse drug reactions in the molecular target drug and a specific adverse event 板垣文雄1), 齋藤ひかり1), 立田澪香1), 戸辺七海1), 前島多絵1), 岩本義弘2), 渡邊真知子1) Journal of Japanese Society of Pharmaceutical Oncology 36: 429-429, 2024. |
|---|
|
|
P-206. About the maintenance of the test result confirmation system in our hospital 中村真一, 上田江利子 Journal of Japanese Society of Pharmaceutical Oncology 36: 430-430, 2024. |
|---|
|
|
P-207. About the permanent residence to a foreign chemotherapy room and cooperation full addition calculation start 岡野芳彦1), 市川卓哉2), 田久保碧1), 吉田優1), 山崎智世1), 豊田真史1), 深野光司1) Journal of Japanese Society of Pharmaceutical Oncology 36: 431-431, 2024. |
|---|
|
|
P-208. Examination of the usefulness of the tracing report in the foreign chemotherapy and the medical economic effect 鈴木健太1), 原幸稔2), 仙波秀彦1), 松本大吾1), 三宮忠1) Journal of Japanese Society of Pharmaceutical Oncology 36: 432-432, 2024. |
|---|
|
|
P-209. Family drugstore investigation of the cooperation enhancement addition calculation patients who worked for the number of participants increase of medicine medicine cooperation Network "Polaris" 長山佳之, 小川千晶, 工藤彰, 長尾嘉真, 石嶋麗, 今村有那, 大塚健太郎, 大栗宝子, 大塚知信 Journal of Japanese Society of Pharmaceutical Oncology 36: 433-433, 2024. |
|---|
|
|
P-210. The results report of the tracing report in outpatient department anticancer medicine-treated patients 藤村拓也1), 三嶋直輝1), 小林美帆1), 畑賢太1), 神垣輝美1), 相馬まゆ子1), 今田愛也2), 西村光弘1) Journal of Japanese Society of Pharmaceutical Oncology 36: 434-434, 2024. |
|---|
|
|
P-211. Of the intervention of the cancer medical therapy support team, actually 宮田智陽1), 杉山昌秀1), 篠原佳祐1), 吉池麻衣1), 原あや乃1), 三浦篤史1), 長瀬通隆2), 國枝献治2), 眞田まきえ3), 新井まき枝3), 大久保由美3), 宮田佳典2) Journal of Japanese Society of Pharmaceutical Oncology 36: 435-435, 2024. |
|---|
|
|
P-212. Efforts for oral cancer Yakuin Todokoro of our hospital 飯嶋歩, 畠山卓, 掛札聡美, 小林美佳 Journal of Japanese Society of Pharmaceutical Oncology 36: 436-436, 2024. |
|---|
|
|
P-213. Influence to the community pharmacy by the reporting about cancer chemotherapy that a specialized medical institution cooperation drugstore provides 宮川丈史, 竹内進, 大房洋一, 瀧谷栞, 江良武弘, 一方井優樹 Journal of Japanese Society of Pharmaceutical Oncology 36: 437-437, 2024. |
|---|
|
|
P-214. Examination of the current situation investigation of the cancer medicine medicine cooperation using the questionary survey and the future problem 和佐野英子, 三好孝法, 深澤真実, 高武嘉道, 菊地憂衣, 大橋邦央, 藤瀬陽子, 橋本雅司 Journal of Japanese Society of Pharmaceutical Oncology 36: 438-438, 2024. |
|---|
|
|
P-215. Efforts of the pharmaceutical medicine cooperation in the medical therapy Abemaciclib supporting after the operation 武井大輔1), 松坂和正1), 直井美萌1), 鈴木貴之1), 中山季昭1), 藤本祐未2), 永井成勲2), 大塚公庸1) Journal of Japanese Society of Pharmaceutical Oncology 36: 439-439, 2024. |
|---|
|
|
P-216. Investigation about the efforts which introduced QR cord into the addition of follow-up contents and an information sharing method to a public chemotherapy regimen 佐藤実由, 古谷智裕, 武井秀樹, 金田公平, 村上礼隆, 阪田安彦, 北本真一, 宮森伸一 Journal of Japanese Society of Pharmaceutical Oncology 36: 440-440, 2024. |
|---|
|
|
P-217. Cooperation with the dietitian in patients who received foreign chemotherapy 黒川咲子1), 佐々木茂文1), 太田晴子2), 堤栄二1) Journal of Japanese Society of Pharmaceutical Oncology 36: 441-441, 2024. |
|---|
|
|
P-218. About efforts to cooperation full addition calculation in our hospital 渡瀬美登里1), 大森淳史1), 川田菜央1), 井上曜1), 古賀悦子2), 吉田真一郎3), 久賀康治3), 坂本欣直1) Journal of Japanese Society of Pharmaceutical Oncology 36: 442-442, 2024. |
|---|
|
|
P-219. About a change and the current situation report of the number of submissions of the tracing report after the number of calculation of the cooperation full addition, the study session enforcement and the problem from the outside Parliament drugstore 高木淳也, 海野祥生, 生田和之, 前田美紀, 鹿間友絵, 木原星衣, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 36: 443-443, 2024. |
|---|
|
|
P-220. Recognition and problem of information sharing contents about the cancer medicine medicine cooperation in Minami-ku, Yokohama-shi 本間愛梨1), 近藤潤一1), 津野丈彦1), 小杉三弥子1), 眞弓純2), 佐橋幸子1) Journal of Japanese Society of Pharmaceutical Oncology 36: 444-444, 2024. |
|---|
|
|
P-221. The current situation investigation in the need of the cooperation system by hospital pharmacist and the health insurance pharmacy pharmacist for the HBV reactivation prophylaxis 内山友輝1), 古川卓也2), 丸山晴生2) Journal of Japanese Society of Pharmaceutical Oncology 36: 445-445, 2024. |
|---|
|
|
P-222. Evaluation of the medicine medicine cooperation about cooperation full addition in our hospital 酒井良隆 Journal of Japanese Society of Pharmaceutical Oncology 36: 446-446, 2024. |
|---|
|
|
P-223. The cooperation full addition in the Niigata Municipal Hospital and the current situation and problem of the medicine medicine cooperation 村越真人, 武藤浩司, 田中裕子 Journal of Japanese Society of Pharmaceutical Oncology 36: 447-447, 2024. |
|---|
|
|
P-224. About the fact-finding of the tracing report for the health insurance pharmacy through efforts and the local pharmacist society of the cooperation full addition in our hospital 村上明男1), 宇津木直人2), 新井聡子1), 安森奈緒子1), 中野涼太3), 濱野愛里1), 白鳥瞳1), 伊東英子1), 五十嵐昌子1), 軍司剛宏1) Journal of Japanese Society of Pharmaceutical Oncology 36: 448-448, 2024. |
|---|
|
|
P-225. Efforts of the pharmacy for the CAR-T cellular therapy in the Mie University faculty of medicine hospital 山田真帆1), 世古口典子1), 須藤あかり1), 加藤千佳1), 石橋美紀1), 川瀬亮介1), 向原里佳1), 伊野和子2), 大石晃嗣2,3), 俵功2), 岩本卓也1) Journal of Japanese Society of Pharmaceutical Oncology 36: 449-449, 2024. |
|---|
|
|
P-226. Efforts and healthcare worker education for the purpose of the improvement in understanding of the patients using the reversely discounted irAE measures card 渡邉大毅1), 武川奈央1), 高成浩史1), 菊池健1), 水野真美子2), 剱持喜之3) Journal of Japanese Society of Pharmaceutical Oncology 36: 450-450, 2024. |
|---|
|
|
P-227. The current situation of the cancer cooperation tracing report in our center 森本奈緒美, 星田唯史, 武田祐子, 藤原大一朗, 眞下惠次, 野田明宏, 田辺和史 Journal of Japanese Society of Pharmaceutical Oncology 36: 451-451, 2024. |
|---|
|
|
P-228. Everywhere in illness medicine cooperation - "for patients with breast cancer using the exclusive medication reporting book, it is ... for the breast cancer treatment that there is" difference in nobody in the same way 菅野友美1), 松本僚1), 加登遼典1), 元村雅1), 河合優太朗1), 桑原勝太1), 田中玖実2), 阿左見亜矢佳3), 阿左見祐介3), 岩上泰崇4), 渡邉絵里子5) Journal of Japanese Society of Pharmaceutical Oncology 36: 452-452, 2024. |
|---|
|
|
P-229. Investigation of the inflection situation of the actual situation and the tracing report of the reporting in foreign cancer treatment of our hospital 坂口哲陛, 田口亮平, 飯干佳徳, 三樹修一 Journal of Japanese Society of Pharmaceutical Oncology 36: 453-453, 2024. |
|---|
|
|
P-230. Enforcement ... of making and the practice type workshop of the efforts - cancer chemotherapy cooperation sheet of the medicine medicine cooperation reinforcement in the cancer chemotherapy 花岡容子, 森川剛, 小池恵理, 寺島孝徳, 清野義一, 岡澤香津子 Journal of Japanese Society of Pharmaceutical Oncology 36: 454-454, 2024. |
|---|
|
|
P-231. We were able to see it from the questionnaire after ... combination study session about medicine medicine cooperation of the chemotherapy in our hospital 吉田幸史, 平田司, 柴田亜由美, 横山友美, 染谷真理子, 橋本佳奈, 土谷隆紀 Journal of Japanese Society of Pharmaceutical Oncology 36: 455-455, 2024. |
|---|
|
|
P-232. Efforts to a task share task shift in the cancer chemotherapy 小材直人, 千吉良幸子, 西場弘美, 新木美枝, 蟻川勝 Journal of Japanese Society of Pharmaceutical Oncology 36: 456-456, 2024. |
|---|
|
|
P-233. Examine medicine medicine cooperation, illness of our hospital; efforts to cooperation 大谷祐子, 金安真由子, 藤井実穂, 出井枝里子, 村田和歌子, 安達嘉織, 合田泰志 Journal of Japanese Society of Pharmaceutical Oncology 36: 457-457, 2024. |
|---|
|
|
P-234. Examination of the regimen by the multi-type of job for anticancer medicine administration time for multiple myeloma shortening for ambulant treatment patients 濱中悠賀1), 栗原りか1), 中野美知子2), 山田はるえ2), 新行内健一1), 伊藤博1), 松本守生3), 金井貴充1) Journal of Japanese Society of Pharmaceutical Oncology 36: 458-458, 2024. |
|---|
|
|
P-235. Effect - of recognition and the multi-type of job cooperation workshop of efforts - health insurance pharmacy pharmacist of regional alliances for the immune-mediated adverse event management 山田稜1), 菊地正史1), 今野壮太1), 押切華映1), 堀川美帆1), 赤坂和俊1), 五十嵐敏明1), 佐藤裕1), 松浦綾子2), 原田成美3), 眞野成康1) Journal of Japanese Society of Pharmaceutical Oncology 36: 459-459, 2024. |
|---|
|
|
P-236. Analysis of workshop enforcement and the questionary survey for the health insurance pharmacy pharmacist aiming at medicine medicine cooperation promotion in the appearance care 奥田真優, 清水絢子, 長谷川拓也, 宇山佳奈, 小泉宏史, 坂本靖宜, 井出和男, 小池博文, 佐橋幸子 Journal of Japanese Society of Pharmaceutical Oncology 36: 460-460, 2024. |
|---|
|
|
P-237. What is demanded from hospital pharmacist for improvement in quality of the foreign palliative treatment 萩原智暉, 神隆浩, 阿蘇拡樹, 大木稔也 Journal of Japanese Society of Pharmaceutical Oncology 36: 461-461, 2024. |
|---|
|
|
P-238. Our hospital's efforts to introduce trastuzumab deruxtecan 市川和幸, 佐久間隆幸 Journal of Japanese Society of Pharmaceutical Oncology 36: 462-462, 2024. |
|---|
|
|
P-239. Regional alliances between the pharmacists by the Kawagoe cancer medical therapy workshop 小澤明香, 大矢浩之, 島田佳実, 森本真宗, 大野悟史, 鈴木宏和, 齋藤健一, 近藤正巳 Journal of Japanese Society of Pharmaceutical Oncology 36: 463-463, 2024. |
|---|
|
|
P-240. About 3 hospital combination workshops to the health insurance pharmacy in the Matsumoto area 巣山悟1), 中村久美1), 鬼窪利英1), 寳福誠2), 内藤隆文3) Journal of Japanese Society of Pharmaceutical Oncology 36: 464-464, 2024. |
|---|
|
|
P-241. About the regional alliances side effect management of the Abemaciclib 田頭尚士1), 山口千尋1), 柏原志保1), 景山康二郎1), 安部裕美1), 西田朋洋1), 坂本靖之1), 川又あゆみ2), 小林美恵2), 吉山知幸2), 藤田秀樹1) Journal of Japanese Society of Pharmaceutical Oncology 36: 465-465, 2024. |
|---|
|
|
P-242. A risk and measures in our hospital of the Fujitsu electronic medical chart regimen system 北原正之 Journal of Japanese Society of Pharmaceutical Oncology 36: 466-466, 2024. |
|---|
|
|
P-243. The effectiveness of the problem extraction by the environmental monitoring using the HD check system 鈴木訓史, 東敬太, 小林美奈子, 唐芳浩太, 内藤義博 Journal of Japanese Society of Pharmaceutical Oncology 36: 467-467, 2024. |
|---|
|
|
P-244. The use situation investigation of the naldemedine in our hospital 上原子順子, 成田未央, 木村弓子 Journal of Japanese Society of Pharmaceutical Oncology 36: 468-468, 2024. |
|---|
|
|
P-245. The effect that drug parenteral injection composition tabulation in the mild medical care gives to the duties efficiency of the pharmacist 寺坂裕希, 黒岩亮平, 亀井陽子, 松沼篤, 興野克典, 町田充 Journal of Japanese Society of Pharmaceutical Oncology 36: 469-469, 2024. |
|---|
|
|
P-246. Inspection of the continuous QALY evaluation of the high-risk medicine remedy patients in the health insurance pharmacy 月岡良太1), 市村丈典2), 小川千晶3), 辻将成1), 村田勇人4), 宮原克明4), 宮田広樹5), 弓削吏司5), 角佳亮6), 吉村朋展7), 鈴木賢一8), 野村久祥9), 清水久範10) Journal of Japanese Society of Pharmaceutical Oncology 36: 470-470, 2024. |
|---|
|
|
P-247. Result and evaluation of the effectiveness that a foreign charge pharmacist intervened in for the patients who visited a hospital for treatment in foreign cancer chemotherapy and a cancerous pain relief purpose in our hospital 中野悠馬, 諸隈梨華, 加藤水月, 岡田侑奈, 大野豊 Journal of Japanese Society of Pharmaceutical Oncology 36: 471-471, 2024. |
|---|
|
|
P-248. Usefulness of the interview method using the side effect interview sheet every regimen 岩部寛之1), 新居由規2), 岡田千都子2), 玉木真紀子1), 伊原木沙智代1) Journal of Japanese Society of Pharmaceutical Oncology 36: 472-472, 2024. |
|---|
|
|
P-249. Examination ... of the thrombosis onset situation in patients who received cancer chemotherapy and the thrombosis risk due to investigation - new model coronavirus infection of the risk factor 山崎智世, 岡野芳彦, 小竹美穂, 深野光司 Journal of Japanese Society of Pharmaceutical Oncology 36: 473-473, 2024. |
|---|
|
|
P-250. Decontamination effect of the low-concentrated ozone gas on in-hospital environmental exposure with the anticancer medicine 野口祥紀, 小川晃宏, 中西由衣, 三宅知宏 Journal of Japanese Society of Pharmaceutical Oncology 36: 474-474, 2024. |
|---|
|
|
P-251. About the activity of the clinical studies adopted in the innovative cancer medical care practical use study business and innovative cancer research support room 佐野慶行, 石橋幸江, 関矢聡, 神野美里, 森田智子, 三浦浩二, 青柳一彦, 竹下文隆 Journal of Japanese Society of Pharmaceutical Oncology 36: 475-475, 2024. |
|---|
|
|
P-252. Fact-finding of the shift situation from tramadol in patients with cancer pain to strong opioid 大野孝明, 新井聡子, 濱野愛里, 村上明男, 五十嵐昌子, 軍司剛宏 Journal of Japanese Society of Pharmaceutical Oncology 36: 476-476, 2024. |
|---|
|
|
P-253. Examination of the reply to cancer chemotherapy, palliative care patients factor of the follow-up utilizing SMS 北田優介1), 笹原侑佑2) Journal of Japanese Society of Pharmaceutical Oncology 36: 477-477, 2024. |
|---|
|
|
P-254. A change of the preparation time accompanied with the dilution apothecaries measure change for rituximab and effect on onset of infusion reaction 春田貴史1), 柿内みず季1), 齊藤菜奈1), 内藤梨奈1), 高橋信1), 本村小百合2) Journal of Japanese Society of Pharmaceutical Oncology 36: 478-478, 2024. |
|---|
|
|
P-255. Quantity of exposure investigation at use of isolator in the anticancer agent preparation and preparation robot 橋爪瞳, 近藤潤一, 栗島直希, 牛島大介, 津野丈彦, 小杉三弥子, 佐橋幸子 Journal of Japanese Society of Pharmaceutical Oncology 36: 479-479, 2024. |
|---|
|
|
P-256. Examination about the usefulness of the telephone call for the patients who conducted chemotherapy introduction during hospitalization 鈴木孝典1), 荒川大輔1), 石野清亮1), 佐原百合名1), 瀧口晶子1), 古橋瞳1), 古橋侑樹2), 矢部勝茂1) Journal of Japanese Society of Pharmaceutical Oncology 36: 480-480, 2024. |
|---|
|
|
P-257. Fact-finding about pharmacist duties and the regional alliances of the foreign cancer treatment section in the 2023 cancer practice cooperation base Hospital, and the like 浮谷聡1,13), 高橋郷2,13), 本田泰斗3,13), 飯塚雄次4,13), 佐々木駿一5,13), 盛川敬介6,13), 餅原弘樹7,13), 内坪敬太8,13), 田島亮9,13), 石原由起子10,13), 濃沼政美11,13), 松井礼子12,13) Journal of Japanese Society of Pharmaceutical Oncology 36: 481-481, 2024. |
|---|
|
|
P-258. Examination about the multiplication analgesic effect by tapentadol and the strong opioid analgesic combination for the cancer pain 慶元箕1,2), 伊東俊雅1,2), 周治由香里1,2), 金杉恵1,2) Journal of Japanese Society of Pharmaceutical Oncology 36: 482-482, 2024. |
|---|
|
|
P-259. Comparison about the filling pressure at medicinal solution filling in the infusor pump 村永諒, 坂田幸雄, 山内聖也, 早川実優, 丸山あゆみ, 吉田壘, 神佳祐, 江畑明日実, 工藤奈々子, 算用子利恵, 山本いずみ, 中嶋紘文, 長浜谷耕司 Journal of Japanese Society of Pharmaceutical Oncology 36: 483-483, 2024. |
|---|
|
|
P-260. Efforts of the drug duties start in the foreign chemotherapy room 宍倉啓介, 小川侑乃, 吉田美和, 山口智 Journal of Japanese Society of Pharmaceutical Oncology 36: 484-484, 2024. |
|---|
|
|
P-261. Attitude survey of the current situation and the healthcare worker of the patients self-care of the drug for the medical care in our hospital 河野渉, 小原徹也 Journal of Japanese Society of Pharmaceutical Oncology 36: 485-485, 2024. |
|---|
|
|
Clinical tumor Pharmaceutical Society (JASPO) member fact-finding 2023 results report in Japan 佐藤由美子1,2), 畠山智明1,3), 齋藤瑛一1,4), 中島美紀1,5), 前原央奈1,6), 田中智枝1,7), 虎石竜典1,8), 笹津備尚1,9), 小笠原信敬1,10), 長久保久仁子1,11) Journal of Japanese Society of Pharmaceutical Oncology 36: 486-486, 2024. |
|---|
